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The term “epilepsy” encompasses a number of different syndromes whose key 
feature is defined by recurrent, unprovoked seizures (Berg et al. 2010). Epilepsy is 
one of the most common chronic neurologic diseases worldwide with a prevalence of 
0.5-1% and a lifetime incidence of 3% (Hauser et al., 1993). Recurrent seizures 
critically change quality of life, particularly of those 30% of epilepsy patients who are 
drug-resistant (Berg et al., 2009). The economic burden of epilepsies is high, it has 
been estimated that the 6 million people with active epilepsy in Europe cost over €20 
billion per year (Cross et al., 2011; www.who.int).  
Epilepsy syndromes are highly heterogeneous in their clinical manifestation. In 1989, 
the International League Against Epilepsy (ILAE) proposed a classification scheme 
(Commission on Classification and Terminology of the International League against 
Epilepsy, 1989.) which has been revised in recently (Berg et al., 2010). Epilepsy 
syndromes are classified by their etiology and symptomatology. Symptomatic 
epilepsy is considered an acquired disorder, developing in response to congenital or 
acquired brain insults such as malformations, tumors or infections. Genetic (formerly: 
idiopathic) epilepsies represent about 40% of all epilepsies in childhood and 
approximately 20% of epilepsies in adulthood (Steinlein et al., 1999). Off note, due to 
our previous studies on the same patient cohort, before classification change, we 
keep in the presented follow up studies in this dissertation the term "idiopathic" 
(Commission et al.,1989) epilepsies instead of "genetic" (Berg et al., 2010) 
epilepsies. Idiopathic (genetic) epilepsies are characterized by recurrent seizures in 
otherwise healthy individuals. The absence of known or suspected cerebral lesions 
and their familial aggregation implicated a genetic basis (Ottman, 2005). Given the 
strong impact of genetic factors in the pathogenesis of idiopathic epilepsies, 
molecular genetic studies provide a promising approach to dissect the responsible 
susceptibility genes and to determine molecular pathways in epileptogenes. The 
most common forms of idiopathic epilepsies include the generalized i) idiopathic 
generalized epilepsy (IGE) and the focal ii) rolandic epilepsy (RE) (Figure 1). 
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Figure 1 Overview of common idiopathic epilepsy types. The epilepsy types are distributed by age of onset as well as 
seizure type. Abbreviations: JAE= Juvenile absence epilepsy; JME= Juvenile myoclonic epilepsy; CAE= Childhood absence 
epilepsy; RE= Rolandic epilepsy; ARE= Atypical rolandic epilepsy. 
 
1.2 Idiopathic epilepsies investigated 
1.2.1 Idiopathic generalized epilepsies (IGE) 
The group of idiopathic generalized epilepsies (IGEs) represent about one-third of all 
epilepsies (Jallon et al., 2011). These epilepsies are characterized by their age-
related manifestation of generalized seizure types (Nordli et al., 2005). Generalized 
spike-wave discharges are the characteristic electroencephalographic signature, 
which reflects a synchronized hyperexcitable state of thalamocortical circuits 
(Blumenfeld et al., 2005). IGEs can be clinically subdivided by leading seizure types 
and age-of-onset into four major IGE syndromes: childhood absence epilepsy (CAE), 
juvenile absence epilepsy (JAE), juvenile myoclonic epilepsy (JME) and epilepsy with 
generalized tonic–clonic seizures alone (EGTCS). In addition, a large variety of other 
genetic epilepsies exist, however, quantitatively they represent a small minority of 
less than 10% (Nordli et al., 2005). The characteristic seizure types of the common 
IGE syndromes are absence seizures (CAE and JAE), bilateral myoclonic seizures 
on awakening (JME) and generalized tonic–clonic seizures (EGTCS). Family and 
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twin studies suggest a predominant genetic predisposition of common IGE 
syndromes with heritability estimates up to 80% (reviewed in Helbig et al., 2008). 
1.2.1.1 Genetics 
A significant complex genetic predisposition is indicated by concordance rates of 70–
80% for IGE in monozygotic twin pairs (Berkovic et al., 1998) compared to rapidly 
declining recurrence risks of IGEs in siblings ranging from four to 10% depending on 
the IGE subtype (Beck-Mannagetta et al., 1991). IGEs follow a complex mode of 
inheritance, suggesting that several genetic factors contribute to generalized seizures 
(Greenberg et al., 1992; Sander et al., 1996; Berkovic et al., 1998). The recurrence 
risk for IGE ranges from 70% to 95% in monozygotic twins and is 10- to15-fold higher 
than for first-degree relatives (5–8%), and more than 100-fold greater than the 
prevalence of 0.6% in the general population (ratio of sibling risk to population 
prevalence: λS ≈ 8) (Sander et al., 1996). However, CAE, JAE and JME cluster in 
families, and, frequently, absence seizures are followed by myoclonic seizures in the 
same patient in an age-dependent manner. These observations support the 
neurobiological concept that the common IGE subtypes share an overlapping genetic 
predisposition (Berkovic et al., 1987; Beck-Mannagetta et al., 1991; Reutens et al., 
1991; Wirrell et al., 1991; Janz et al., 1997). Furthermore, supporting this concept, 
the age-related expression of various seizure types arises from a genetically 
determined impairment of brain maturation or is influenced by the stage of brain 
maturation (Shinnar et al., 1991). In rare monogenic types of idiopathic epilepsies, 
several genes have been identified of which the majority of genes encode voltage-
gated or ligand-gated ion channels (e.g. SCN1A, GABRA1, KCNQ2, KCNQ3, 
CHRNA4 and many others) (Reid et al., 2009). The molecular dissection of genes 
conferring susceptibility to the genetically complex idiopathic epilepsies remains a 
challenge. In contrast to gene mapping strategies applied in rare monogenic 
epilepsies, a large number of linkage and candidate gene association studies failed 
to identify susceptibility genes for common IGE syndromes with complex genetic 
predisposition (Gardiner, 2005; Hempelmann et al., 2006; Kasperaviciute et al., 2010; 
Greenberg and Subaran, 2011). The failure to identify replicable risk genes for 
common epilepsies most likely reflects the underestimated degree of genetic 
complexity and heterogeneity in human epilepsies. 
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1.2.2 Rolandic epilepsy (RE) and the RE spectrum 
Benign epilepsy with centrotemporal spikes (BECTS) was first described by Martinus 
Rulandus in 1597 (Van Huffelen, 1989). The syndrome is now named rolandic 
epilepsy (RE) because of the characteristic features of partial seizures involving the 
brain region around the lower portion of the rolandic fissure. RE is one of the most 
common epilepsy syndromes in children, accounting for about 15 % of epilepsies 
beginning before the age of 16 years (Freitag et al., 2001; Shinnar et al., 2002). 
Onset typically occurs from 4–12 years in otherwise healthy children (Lerman et al., 
1986). Seizures have a focal origin and frequently start with one-sided sensorimotor 
symptoms of lips tongue, and face, resulting in hypersalivation and speech arrest 
(summarized by Strug et al., 2009). The prognosis of RE is benign. It resolves 
spontaneously and by far of most affected children remain intellectually normal. 
There is, however, an increased comorbidity with attention deficit hyperactivity 
disorder (ADHD) and specific mild cognitive deficits (approx. 20%) (Smith et al., 
2012). 
RE is related to much rarer, and less benign epilepsy syndromes, including atypical 
benign partial epilepsy of childhood (ABPE), Landau-Kleffner syndrome (LKS) and 
epileptic encephalopathy with continuous spike-and-waves during sleep (CSWSS) 
(Doose et al., 2001; Gobbi et al., 2006; Guerrini and Pellacani, 2012; Hahn et al., 
2001), referred to as RE related syndromes, or atypical rolandic epilepsy (ARE) by 
some authors (Fejerman, 2009). RE and the ARE share blunt, high-voltage, 
characteristically shaped centrotemporal spikes (CTS) of characteristic morphology in 
the EEG. However, ARE denote more severe forms of focal childhood epilepsies with 
various additional seizure types, developmental language delay or regression, 
speech dyspraxia and variable neuropsychiatric deficits in up to 50% of the affected 
(Gobbi et al., 2006; Hughes et al., 2011). 
1.2.2.1 Genetics 
The majority of RE patients have a complex genetic predisposition as implicated by 
the relative decline of the recurrence risks of seizures in 9.8% of first-degree 
relatives, 3% in second- and 1.5% in third-degree relatives as well as the intriguing 
phenotypic variability observed among family members (Vears et al., 2012). The age-
dependent EEG endophenotype of centrotemporal sharp waves (CTS) represents 
the electroencephalographic hallmark of RE. The CTS-EEG may also be present in 
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clinically unaffected family members and was earlier reported to be inherited in an 
autosomal-dominant manner (Heijbel et al., 1975; Bali et al., 2007). However these 
findings were questioned for methodological reasons (Ottman et al., 1989) ARE 
belongs to an extended spectrum of Rolandic epilepsy, a rate of 40% EEG 
concordance for siblings investigated at the age of maximum expression (3 to 10 
years) is observed (Doose et al., 2001). Despite the strong genetic predisposition of 
the CTS-EEG trait, the etiology of epilepsies with centrotemporal spikes is largely 
unknown. Various loci have been reported for classic or rare forms of RE (Scheffer et 
al., 1995; Neubauer et al., 1998; Guerrini et al., 1999; Roll et al., 2006; Strug et al., 
2007; Strug et al., 2009). 
Furthermore, rare variants in KCNQ2, KCNQ3 and SRPX2 have been associated 
with the RE or ARE in small subsets of patients (Neubauer et al., 2008; Roll et al., 
2006). Recently, rare structural variations at 16p13 deleting the genomic region of 
GRIN2A have been observed for patients with ARE (Reutlinger et al., 2010). All these 
variants and loci have never been replicated and might account for only a small 
fraction of the genetic risk for the rolandic epilepsies, whereas the major cause(s) 
remain unknown. 
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2 Goals and objectives 
The aim of the present studies was the molecular genetic dissection of risk factors 
with strong epileptogenic effects in idiopathic epilepsies (Figure 2) and the 
elucidation of their molecular pathways in epileptogenesis. Taking into account the 
low power of our case-control study for genome-wide scans, our current strategy 
focused on a candidate gene/locus approach of genes and CNVs that have either 
been implicated in the pathogenesis of epilepsy or represent plausible candidate 
genes with a presumed impact on neuronal excitability. This candidate gene/locus 
approach was restricted to the identification of genetic risk factors with a strong 
impact on epileptogenesis according to the common disease-rare variant (CD-RV) 
model (Pritchard, 2001; McClellan et al., 2007). The CD-RV model implies that 
multiple, heterogeneous rare variants with strong effects contribute to the genetic 
architecture underlying common idiopathic epilepsies. In line with the CD-RV model, 
we had previously demonstrated that large recurrent microdeletions in the 
chromosomal regions 15q11.2, 15q13.3 and 16p13.11 constitute individually rare but 
collectively substantial genetic risk factors of IGE (Helbig et al., 2009; De Kovel et al., 
2010). 
 
Figure 2: Expected distribution of disease variants. Theory on common disease variation predicts a continuum of 
frequency and effect size of disease variants present in the population. Rare high-risk variations are mainly 
expected for Mendelian diseases. Less frequent disease variants with moderate to large effects (highlighted in blue) 
will be detected in our CNV and mutation studies. The figure is modified from McCarthy et al., 2008.   
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Two strategies were applied to identify genetic risk factors for idiopathic epilepsies: 1) 
copy number variation (CNV) analysis using high-resolution SNP arrays and 2) whole 
exome sequencing (WES) to detect mutations in the coding regions. Taking into 
account our cohort sizes and the amount of expected variants, the study power was 
small. Therefore, our analyses focused on genetic variants affecting genes involved 
in neuronal excitability.  
2.1 Discovery cohorts 
The discovery cohorts of idiopathic epilepsies included two case-control cohorts: i) 
1582 unrelated IGE and 2795 populations controls of North-Western European 
descent, and ii) 308 patients with RE-spectrum epilepsies and 1512 controls of 
European descent. In addition, we performed candidate gene sequence analysis in 
242 patients with RE-spectrum epilepsies. The IGE study cohort was collected by a 
European concerted action organized by the EPICURE Consortium (EPICURE 
GWAS discovery cohorts; EPICURE et al., 2012). The standardized ascertainment 
scheme, clinical protocols and diagnostic criteria are available at http://portal.ccg.uni-
koeln.de/ccg/research/epilepsy-genetics/sampling-procedure/. The cohort of 281 
patients with RE–spectrum epilepsies were recruited in the framework of the 
European collaborative research project EuroEPINOMICS. In a multi-centre effort, 
RE/ARE patients were recruited from Germany, Austria, Canada and Australia. 
Ninety-eight of the patients were ascertained through multiplex-families with at least 
two affected siblings. Diagnosis of RE was performed according to the International 
Classification of Seizures and Epilepsies (Commission on Classification and 
Terminology of the International League against Epilepsy 1989; Berg et al., 2010). 
The various syndromes classified as RE-spectrum epilepsies fulfilled the diagnostic 
criteria as specified previously (Aicardi and Chevrie, 1982; Doose et al., 2001; Hahn 
et al., 2001). In total, the discovery cohort comprised 230 patients affected by typical 
RE and 51 patients with ARE (165 males and 116 females). Both screening cohorts 
represent the largest assemblies of IGE and RE/ARE patients reported so far. 
2.2 Molecular genetic screening methods 
The present studies applied two molecular genetic screening techniques to identify 
genetic risk factors with strong effects: i) copy number variation (CNV) analyses 
using high-resolution SNP arrays (IGE and RE cohorts), and ii) candidate gene 
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sequence analysis based on an ongoing whole exome sequencing project (RE/ARE, 
n =242). 
2.3 Selection of candidate genes 
We investigated large recurrent CNVs at 1q21, 15q11.2, 15q13.3, 16p11.2, 16p13.11 
and 22q11.2 (Helbig et al., 2009; Coe et al., 2012; De Kovel et al., 2013); as well as 
the high-ranking candidate genes GRIN2A (Reutlinger et al., 2010; Lesca et al., 
2012), GPHN (Förstera et al., 2010; Lionel et al., 2013), RBFOX1 and RBFOX3 
(Bhalla et al., 2004; Martin et al., 2007; Gallant et al., 2011; Gehman et al., 2011) as 
well as DEPDC5 (Dibbens et al., 2013; Ishida et al., 2013). The investigated CNV loci 
have been implicated in the pathogenesis of epilepsies or other neurodevelopmental 
disorders, whereas the candidate genes are presumed to have a strong functional 
impact in pathways controlling neuronal excitability.  
 
2.4 Scope of the ongoing research activities 
In the presented cumulative thesis I report the results of our current CNV and 
candidate gene sequence analyses resulting in three articles already published in 
peer review journals (Lal et al., 2013a; Lal et al., 2013b, Lemke et al., 2013). Another 
three papers are currently in revision (Lal et al., Dejanovic et al., Reinthaler et al.,). 
Our ongoing studies identified CNVs at 16p11.2, RBFOX1, RBFOX3 and GRIN2A 
and putative deleterious sequence mutations in GRIN2A and DEPDC5 in patients 
with idiopathic epilepsies. These results offer new insight into the genetic architecture 
of common epilepsy syndromes by: i) the delineation of the phenotypic spectrum 
associated with these epilepsy genes, ii) the characterization of their allelic spectra 
and modes of inheritance (de novo, inherited, estimates of the effect size, 
penetrance, expressivity), and iii) a first step in the elucidation of the underlying 
molecular pathomechanisms in epileptogenesis. In the long term, our study results 
might accelerate the prospects to translate the rapidly increasing knowledge into 
clinically relevant actions. 
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3 Publications  
3.1 Publications on IGE  
3.1.1 RBFOX1 in IGE (published) 
Lal D, Trucks H, Møller RS, Hjalgrim H, Koeleman BPC, et al. (2013) Rare exonic deletions 
of the RBFOX1 gene increase risk of idiopathic generalized epilepsy. Epilepsia 54: 265–
271. doi:10.1111/epi.12084
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3.1.2 GPHN in IGE (in revision) 
Dejanovic B*, Lal D*, Catarino BC*, Arjune S et al. Exonic microdeletions of the gephyrin 
gene exert a dominant-negative effect on GABAergic synaptic inhibition in two patients with 
idiopathic generalized epilepsy. Human Molecular Genetics (in revision) 
*These authors contributed equally to this work  
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ABSTRACT 
Gephyrin is a postsynaptic scaffolding protein, essential for the clustering of glycine 
and γ-aminobutyric acid type-A receptors (GABAARs) at inhibitory synapses. An 
impairment of GABAergic synaptic inhibition represents a key pathway of 
epileptogenesis. Recently, exonic microdeletions in the gephyrin gene (GPHN) have 
been associated with neurodevelopmental disorders including autism spectrum 
disorder, schizophrenia and epileptic seizures. Here we report the identification of 
novel exonic GPHN microdeletions in two patients with idiopathic generalized 
epilepsy (IGE), representing the most common group of genetically determined 
epilepsies. The identified GPHN microdeletions involve exons 5-9 (Δ5-9) and 2-3 
(Δ2-3), both affecting the gephyrin G-domain. Molecular characterization of the 
GPHN Δ5-9 variant demonstrated that it perturbs the clustering of regular gephyrin at 
inhibitory synapses in cultured mouse hippocampal neurons in a dominant-negative 
manner, resulting in a significant loss of 2-subunit containing GABAARs. GPHN Δ2-3 
causes a frameshift resulting in a premature stop codon (p.V22Gfs*7) that most likely 
leads to haplo-insufficiency of the gene. Our results demonstrate that structural 
exonic microdeletions affecting the GPHN gene constitute a rare genetic risk factor 
for IGE and other neuropsychiatric disorders by an impairment of the GABAergic 
inhibitory synaptic transmission. 
KEYWORDS 
Idiopathic generalized epilepsy; Microdeletion; GPHN; gephyrin; 
ABBREVIATIONS 
GABAAR, γ-aminobutyric acid type-A receptors; CNV, copy number variations; IGE, 
idiopathic generalized epilepsie; TMS, transcranial magnetic stimulation; DTI, 
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diffusion tensor imaging; HEK293, Human Embryonic Kidney 293; TLE, temporal 
lobe epilepsy; qPCR, quantitative polymerase chain reaction; 
INTRODUCTION 
Epilepsy is characterized by recurrent spontaneous seizures due to a neuronal 
hyperexcitability and an abnormal cortical synchronization. Approximately 3% of the 
general population are affected by epilepsy until the age of 40 years 1. The idiopathic 
generalized epilepsies (IGEs) represent the most common group of genetically 
determined epilepsies, accounting for 20-30% of all epilepsies 2. Their clinical 
features are characterized by age-related recurrent unprovoked generalized seizures, 
in the absence of detectable brain lesions or metabolic abnormalities 3,4. Genetic 
factors play a predominant role in the etiology of IGE with heritability estimates of 
80%. However, the vast majority of IGE syndromes have an oligo-/polygenic 
predisposition and their genetic basis remains elusive 5.  
Structural genomic copy number variations (CNVs) account for a substantial fraction 
of the genetic variance in about 3% of patients with idiopathic epilepsies 6-9. 
Recurrent microdeletions at 15q11.2, 15q13.3, 16p13.11 6,7 and exonic deletions in 
NRXN1 10 and RBFOX1 11 increase the risk of IGE and a wide range of 
neurodevelopmental disorders 12. Recently, exonic microdeletions in the gene 
encoding the synaptic scaffolding protein gephyrin (GPHN) have been found to 
represent a rare cause of neurodevelopmental disorders, including autism spectrum 
disorder (ASD), schizophrenia and epileptic seizures 13. Two out of six patients 
carrying exonic GPHN deletions exhibited seizures 13.  
Gephyrin is a postsynaptic scaffolding protein, essential for the clustering and 
localization of glycine and a subset of GABAA receptors at inhibitory synapses 
14-19. 
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Gephyrin is composed of three domains - the C-terminal E-domain binds directly to 
the glycine and GABAA receptor subunits, whereas the N-terminal G-domain is 
crucial for gephyrin’s oligomerization. Both domains are connected by the central (C) 
domain 18. Aberrant function of gephyrin impairs GABAergic synaptic inhibition, which 
thereby may promote neuronal hyperexcitability and seizure susceptibility. 
Previously, we have reported a gephyrin-specific effect in temporal lobe epilepsy 
(TLE), where stress-induced irregular splicing of GPHN resulted in the expression of 
truncated gephyrin variants that impaired the function of regular gephyrin by 
dominant-negative interaction 20. Additionally, reduced gephyrin expression has been 
detected in temporal lobe surgical specimens of patients with medically refractory 
TLE, as well as in rat models 21. These accumulating lines of evidence support the 
hypothesis that gephyrin dysfunction impairs GABAergic synaptic inhibition and 
thereby contributes to epileptogenesis 21,22. In the present study, we screened the 
GPHN gene for microdeletions in 1469 European patients with common IGE 
syndromes and 2256 population controls 11. We identified exonic GPHN deletions 
affecting the gephyrin N-terminal G-domain in two IGE patients and characterized the 
underlying molecular mechanism causing functional alterations in gephyrin clustering 
thus promoting epileptogenesis.  
MATERIALS AND METHODS 
Study cohort and CNV screening 
This study has been approved by the local Research Ethics Committees. All study 
participants including the family members of the GPHN deletion-carriers provided an 
informed written consent. CNV screening of the genomic GPHN sequence 
(chr14:66,974,125-67,648,525; human genome build 37/hg19) was carried out in 
1,469 unrelated patients with IGE of self-identified North-Western European ancestry 
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and 2,256 German population controls 11. DNA samples were investigated by the 
Affymetrix Genome-Wide Human SNP Array 6.0 (Affymetrix, Santa Clara, CA, USA). 
CNV analysis was performed, using the Birdsuit algorithm implemented in the 
Affymetrix Genotyping Console version 4.1.1. Regional log2 ratios of the signal 
intensities and the SNP heterozygosity state were visualized in the Chromosome 
Analysis Suite v1.2.2 (Affymetrix, Santa Clara, CA, USA). The copy number state of 
the GPHN microdeletions identified by the array-based CNV analysis were examined 
by real-time quantitative PCR (qPCR), using a TaqMan® CNV assays located in 
GPHN exon 7 (Assay ID: Hs01711518_cn) and intron 2 (Assay ID: Hs07084813_cn; 
Life Technologies, Carlsbad, CA, USA). Genome-wide CNV screening beyond the 
GPHN locus was restricted to CNVs with a segment size > 500kb 23 and a minimum 
of 50 markers to achieve a high accuracy and reliability. Again, regional log2 ratios of 
the signal intensities and the SNP heterozygosity state were visualized for all CNVs 
in the Chromosome Analysis Suite v1.2.2 (Affymetrix, Santa Clara, CA, USA) and 
were manually inspected.  
Transcript analysis 
RNA was isolated from whole blood samples using the PAXgene Blood RNA Kit 
(Qiagen, Hilden, Germany). For amplification of the Δ5-9 deletion flanking primers 
were designed: Forward (within exon 4) AGGAACAGGATTTGCACCAC and reverse 
(within exon 13) GCGATGTCTTCTAGCCACCT. Amplification of the Δ2-3 deletion 
was performed with primers: Forward (within exon 1) 
CCGAGGGAATGATCCTTACTAA and reverse (within exon 7) 
TCAAGTTCATCATGCACCTCC. The sizes of the amplified DNA fragments were 
assessed using a 1.5% agarose gel electrophoresis and the Agilent 2200 
TapeStation Nucleic Acid System (Agilent Technologies, Santa Clara, California, 
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USA). Bidirectional Sanger sequencing of the identified GPHN cDNA amplicons was 
done following standard protocols.  
Paired-pulse transcranial magnetic stimulation 
For Family 1, the patient, his father and six healthy controls with no personal history 
of seizures or other neurological disorders and no medication (three females, median 
age 38 years, range 24-44 years) had transcranial magnetic stimulation (TMS). After 
evaluating the resting motor threshold (MT), paired-pulse TMS was used to study 
intra-cortical inhibition (ICI; interstimulus interval [ISI] of 3 ms) and intra-cortical 
facilitation (ICF; ISI of 13 ms). The protocol used was adapted from Werhahn and 
colleagues 24. IBM SPSS Statistics 21.0 software was used for statistical analysis. 
Expression construct  
Regular enhanced green fluorescent protein (EGFP)-tagged gephyrin 25 served as 
the basis for Δ5-9geph expression constructs. Fragments encoding gephyrin exons 
1-4 and 10-30 were amplified from regular gephyrin construct and connected by 
fusion PCR. The two fragments were connected by fusion PCR and introduced into 
the pEGFP-C2 vector (Clontech) using XhoI and HindIII restriction sites. To create 
myc-tagged gephyrin, EGFP-tagged gephyrin was amplified with primers that 
introduce the sequence for the myc-tag (EQKLISEEDL) at the N-terminus of gephyrin 
and a stop-codon after the last amino acid of gephyrin. Fragment was introduced into 
pEGFP-N2 the vector (Clontech, Mountain View, CA, USA) using XhoI and HindIII 
restriction sites.  
Hippocampal neuron cultures and transfection  
Primary neuron cultures were prepared from hippocampi of C57BL/6 mice and plated 
on poly-L-lysine coated coverslips at a density of 75,000/24-well dish. Neurons were 
cultured in Neurobasal medium, supplemented with B-27, N-2 and glutamine. 
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Neurons were transfected after 11 days in vitro (DIV) unless otherwise stated. 
Transfection was carried out with Lipofectamin 2000 (Invitrogen) according to 
manufactures manual. Constructs were expressed for 48 hours unless otherwise 
stated.  
Human embryonic kidney cell culture and transfection  
Human embryonic kidney (HEK293) cells were grown in Dulbecco’s modified Eagle’s 
medium supplemented with 10% fetal calf serum and 2 mM L-glutamine at 37 °C and 
5% CO2. For confocal laser-scanning microscopy, 1 × 10
5 HEK-293 cells were 
seeded on collagenized coverslips in 12-well plates and immediately transfected with 
polyethylenimine (1 mg/ml, diluted in H2O, pH 7.0) using standard protocols. Cells 
were grown for 24-48 h depending on the assay.  
Immunostaining of cultured cells  
Cells were fixed with 4% PFA for 10 min at room temperature. Unspecific binding 
sites were blocked with blocking solution (2% BSA, 10% goat serum, 0.2% Triton X-
100) for 1h and primary antibodies were applied for 1 h in 10% goat serum. After 
three washing steps in PBS, cells were incubated with secondary antibodies in 10% 
goat serum for 1 h at room temperature. After the final three washing steps in PBS, 
slides were mounted on cover slips with Fluoro gel II containing DAPI (Science 
Service, Munich, Germany) to stain the nuclei. Antibodies used for the staining: 
mouse anti-gephyrin (1:50 cell culture supernatant, clone 3B11); rabbit anti-gephyrin 
(1:1,000, rGeph-C, epitope EDLPSPPPPLSPPP, Eurogentec, Belgium); guinea-pig 
anti-GABAA-gamma2 receptor (Jean-Marc Fritschy, ETH, Zurich); rabbit anti-VGAT 
(1:500, Synaptic Systems, Göttingen, Germany); mouse anti-myc-tag (1:10 cell 
culture supernatant, clone 9E10). Secondary antibodies were all goat raised Alexa 
Fluor antibodies (1:500, Invitrogen, Carlsbad, CA, USA).  
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Image analysis and quantification  
Images were acquired with a confocal laser scanning microscope (Nikon A1) at 60x 
using a resolution of 1024x1024. Images were processed using the software NIS 
Elements (NIKON). For analysis of neuronal cultures at least two independent 
preparations per condition were used. Images were acquired as a z-stack with three 
optical sections with 0.5 μm steps. Maximum intensity projections were created and 
analyzed using NIS Elements software. Usually two 20 x 5 μm region of interests 
(ROI) were placed on dendrites and clusters were counted using the analyze 
particles option in NIS Elements. For statistical analysis, gephyrin cluster were 
compared pairwise between EGFP and Δ5-9geph expressing neurons. Mean values 
were compared for significance using Student’s t-test with the software SigmaPlot 
(Systat Software, Chicago, IL, USA). Errors are presented as standard error of the 
mean (SEM). Significance levels are indicated as *P < 0.01, **P < 0.05, ***P < 0.001. 
Images were processed with the software ImageJ (NIH). 
Co-immunoprecipitation 
Protein extracts were prepared in an IP-buffer (25 mM Tris, pH 7.4, 150 mM NaCl, 
1% Triton X-100, protease and phosphatase inhibitor cocktail (Roche, Mannheim, 
Germany)). The post-nuclear fraction was incubated with primary antibodies for 1 h at 
room-temperature or overnight at 4 °C. 20 μl Protein-G Sepharose beads were 
incubated with the extracts for 2 hours at room temperature. After a brief 
centrifugation (500 g for 3 min), the immune-beads were washed three times with IP 
buffer. The adsorbed proteins were eluted from the immune-beads by boiling in 50 μl 
SDS-loading buffer. Immunoprecipitated samples were subjected to SDS-PAGE 
followed by immunoblotting. 
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Western Blot analysis and antibodies  
For immunoblotting, a standard protocol was followed and detection was carried out 
using chemiluminescence and an ECL system with a cooled CCD camera (Decon 
Science Tec, Germany). The following primary antibodies were used and diluted in 
TBS-Tween containing 1% dry-milk: anti-Gephyrin (1:50, clone 3B11 cell culture 
supernatant), rabbit anti-ß-tubulin (1:100, Santa Cruz, Santa Cruz, CA, USA), rabbit 
anti-GFP (1:5,000, Abcam, Cambridge, UK), mouse anti-myc-tag (1:10 cell culture 
supernatant, clone 9E10). As secondary antibodies anti-mouse or anti-rabbit 
conjugates were used in a 1:10,000 dilutions in TBS-Tween containing 1% dry milk.  
 
RESULTS 
Detection of exonic GPHN microdeletions and mRNA transcription analysis 
We screened the genomic GPHN sequence (14q23.3:66,974,124-67,648,524, 
reference coding sequence: NM_020806, CCDS9777.1; hg19) for microdeletions 
(size > 40 kb, number of probe sets > 20) using high coverage microarrays from 
1,469 unrelated European patients with common IGE syndromes and 2,256 German 
population controls. We identified two hemizygous exonic GPHN microdeletions in 
the IGE cohort: i) a 129 kb microdeletion (chr14:67,314,917-67,443,729) affecting 
GPHN exons 5-9 (Δ5-9) in a German male patient with juvenile myoclonic epilepsy 
(JME, Family 1), and ii) a 158 kb microdeletion (chr14:67,136,658-67,295,196) 
encompassing GPHN exons 2-3 (Δ2-3) in a German male patient with myoclonic 
astatic epilepsy (Doose syndrome, Family 2) (Fig. 1A). None of the 2,256 German 
controls carried a microdeletion at the GPHN locus. The hemizygous copy number 
state of the GPHN deletions was validated by TaqMan quantitative PCR (qPCR).  
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Exome sequencing of the GPHN coding regions and exon/intron boundaries did not 
reveal any additional indels and rare missense mutations in the parent-offspring trio 
of Family 1. Direct blood cDNA amplification of GPHN exons 4-13 for Family 1 and 
exons 1-7 for Family 2 followed by Sanger sequencing of the major amplicons 
confirmed the transcription of the truncated GPHN variants and revealed a paternal 
transmission of both microdeletions (Fig. 1B-D and Supplementary Material S1). 
Genome-wide screening for CNVs previously associated with epilepsy 6,8,9,26,27, 
revealed no additional known pathogenic CNVs in both index patients.   
On protein level, the GPHN Δ5-9 microdeletion leads to the truncation of the gephyrin 
G- and C-domain (hereafter termed “Δ5-9geph” - Fig. 1E). Given that residue 22 is 
encoded by a splitted codon composed by exons 1 and 2, the GPHN Δ2-3 variant 
results in a frameshift and a premature stop codon (p.V22Gfs*7, Fig. 1F). We 
assume that, although through first strand synthesis we were able to amplify the 
GPHN Δ2-3 variant, most of the transcript will be degraded by nonsense-mediated 
mRNA decay, a translation-dependent posttranscriptional process that selectively 
recognizes and degrades mRNAs whose open reading frame is truncated by a 
premature translation termination codon 28, resulting in negligible amounts of the 
protein. 
Clinical features of the GPHN deletion carriers and segregation analysis  
Family 1 (GPHN Δ5-9 deletion) 
The pedigree of Family 1 is presented in Fig. 1A. The non-consanguineous German 
parents (57-years-old father, 55-years-old mother) and the patient’s 30-year-old sister 
had no unequivocal history of seizures. The GPHN Δ5-9 deletion was paternally 
inherited. The mother showed a diploid copy number status at the GPHN locus. DNA 
PUBLICATION: GPHN IN IGE 
32 
from the clinically unaffected sister was not available. The 33-year-old male index 
IGE patient was born at term after an uneventful pregnancy and delivery. He had 
recurrent simple febrile seizures from the age of six months to six years, unprovoked 
generalized tonic-clonic seizures since the age of five years and myoclonic seizures 
recorded by video-EEG starting at the age of 16 years. Complete remission of 
epileptic seizures by monotherapy with levetiracetam was reached since the age of 
24 years. Neurological examinations and brain MRIs (3-T) were normal. The epilepsy 
diagnosis was classified as JME. Neuropsychiatric and developmental comorbidities 
were mild deficits in motor coordination, hyperactivity, and learning difficulties during 
childhood. Neuropsychological testing at the age of 19 years showed normal 
cognitive abilities with average performance scores. Recurrent episodes of major 
depression with suicide attempts started at the age of 16 years, accompanied by 
generalized anxiety, panic attacks and phobic vertigo. Non-epileptic psychogenic 
attacks became evident since the age of 32 years. The patient’s father experienced 
three unprovoked events of loss of consciousness between 4 and 6 years of age. 
There is a strong family history of migraine affecting the maternal branch of the 
family. Any history of psychiatric disorders, dysmorphism, developmental delay, 
intellectual disability or miscarriages was absent. 
Neurophysiological examinations 
To evaluate cortical excitability, we performed paired-pulse transcranial magnetic 
stimulation (TMS) in Family 1 29. For both, the JME index-patient and his father, intra-
cortical inhibition was significantly reduced as compared to six healthy controls (P < 
0.001), while intra-cortical facilitation was more pronounced than in controls (P < 
0.001- Fig. 2). Likewise, diffusion tensor imaging (DTI) showed an enhanced 
structural connectivity between the mesial frontal region and the descending motor 
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pathways in the index patient and his father that was beyond the range seen in 
healthy controls (Supplementary Material Fig. S3). For the patient the peak voxels 
reached statistical significance for the connectivity to the motor pathways (P < 0.001), 
whereas the father's values showed only a trend but did not reach statistical 
significance. 
Family 2 (GPHN Δ2-3 deletion) 
The pedigree of Family 2 is presented in Fig. 1A. The non-consanguineous parents 
(50-year-old father, 48-year-old mother) are of German ancestry. The GPHN Δ2-3 
deletion was paternally inherited. The mother and the brother had diploid copy 
numbers at the GPHN locus. The 16-year-old male index IGE patient was affected by 
febrile seizures at the age of 15 months and by myoclonic astatic seizures starting at 
the age of 1.5 years. Since antiepileptic treatment with valproate, which was started 
shortly after epilepsy-onset, he is seizure-free. The EEG exhibited irregular sharp-
slow wave discharges at 3-Hz. The patient showed a normal physical but delayed 
cognitive development with persistent learning disability. His epilepsy was classified 
as idiopathic myoclonic-astatic epilepsy (Doose syndrome). The father had no history 
of seizures and a normal psychomotor development. The mother experienced three 
seizures during infancy with spontaneous remission and normal psychomotor 
development. Her EEGs displayed interictal epileptiform discharges. The 18-year-old 
brother of the index patient had two febrile seizures during childhood while no 
subsequent history of afebrile seizures, normal psychomotor development and EEG 
were reported. None of the family members had a history of psychiatric disorders.  
Molecular and biochemical characterization of the GPHN Δ5-9 variant 
Gephyrin forms postsynaptic clusters along the neurites as well as soma, while 
following its overexpression in non-neuronal cells, it forms cytosolic protein-
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aggregates (“blobs”, Fig. 3A,B). To examine the effects of the GPHN Δ5-9 deletion, 
we expressed GFP-tagged Δ5-9geph in cultured hippocampal neurons and HEK293 
cells. Δ5-9geph-GFP was homogenously distributed in the cytosol of HEK293 cells 
and neurons including all morphological structures, i.e. spines (Fig. 3A,B), suggesting 
its inability of form postsynaptic clusters. To see how clustering deficient Δ5-9geph 
influences regular gephyrin, we first co-expressed myc-tagged gephyrin and Δ5-
9geph-GFP in HEK293 cells. We found that gephyrin blobs were dissolved resulting 
in either diffuse regular gephyrin or the formation of microclusters co-localizing with 
Δ5-9geph-GFP (Fig. 3C,D). This demonstrates a dominant-negative effect of Δ5-
9geph on the oligomerization of regular gephyrin. Notably, Δ5-9geph-GFP was stably 
expressed at levels equivalent to regular gephyrin-GFP (Fig. 3E). The observed 
dominant-negative effect on regular gephyrin clustering is mediated by direct 
interaction with Δ5-9geph, as shown by co-immunoprecipitation (Fig. 3F).  
To evaluate the consequences of dominant-negative Δ5-9geph action on neuronal 
gephyrin clustering, we expressed Δ5-9geph-GFP or GFP alone in cultured 
hippocampal neurons. To distinguish between endogenous gephyrin and Δ5-9geph-
GFP, we used a monoclonal antibody against a peptide in the C-domain that is 
deleted in Δ5-9geph (rGeph-C, Fig. 4A). Expression of Δ5-9geph-GFP significantly 
reduced the number of endogenous gephyrin clusters confirming the previously 
stated dominant-negative effect (Fig. 4B,C). Moreover, remaining gephyrin clusters 
were significantly reduced in size indicating that Δ5-9geph disturbs the clustering of 
regular gephyrin (Fig. 4D). To determine how Δ5-9geph-GFP expression influences 
the clustering of GABAARs, we visualized the γ2-subunit (Fig. 4E), which plays a 
central role in gephyrin-dependent postsynaptic clustering of GABAARs 
30,31. Number 
and cluster size of γ2-containing GABAARs were significantly decreased in the 
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presence of Δ5-9geph-GFP (Fig. 4F,G). Together with the observed reduced quantity 
of gephyrin clusters, our data imply that receptor homeostasis responds to decreased 
amounts of clustered gephyrin.  
To investigate whether Δ5-9geph-mediated reduction in GABAergic innervation 
influences synaptic spines, typical morphological structures of the excitatory synapse 
32, we visualized spines in control and Δ5-9geph-GFP-expressing neurons by 
thresholding the EGFP-signal to an identical value. Spine head morphology and 
amount was similar in EGFP and Δ5-9geph-expressing neurons, suggesting that 
diminished GABAergic synapses did not interfere with synaptic spines (Fig. 4H-J).  
Besides its synaptic function, gephyrin catalyzes the last step of the molybdenum 
cofactor (Moco) biosynthesis being essential for the activity of four molybdenum-
dependent enzymes 33-35. We measured typical urinary biomarkers of two Moco-
dependent enzymes, xanthine oxidase (uric acid, xanthine) and sulfite oxidase (S-
sulfocysteine) as well as the Moco degradation product urothion 36,37 in the patient 
and his parents of Family 1. Concentrations of all analyzed metabolites were 
inconspicuous, suggesting that the hemizygous GPHN Δ5-9 variant did not cause 
any subclinical Moco deficiency phenotype in the affected patient (Supplementary 
Material Fig. S3).  
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DISCUSSION 
We present a comprehensive clinical, genetic, functional and neurophysiological 
characterization of two IGE patients with novel hemizygous microdeletions 
encompassing GPHN exons that code for the N-terminal gephyrin G-domain. Our 
finding strengthens a previous report of six unrelated subjects with a wide range of 
neurodevelopmental disorders (ASD, schizophrenia, seizures) who carried 
hemizygous GPHN microdeletions affecting the gephyrin G-domain 13, and extends 
the phenotypic spectrum related to N-terminal GPHN microdeletions by IGE 
syndromes (Supplementary Material Fig. S4). The study reported by Lionel et al. 
deduced evidence of pathogenicity of GPHN microdeletions from the significant 
association with neurodevelopmental disorders (P = 0.009; 6/8,775 cases versus 
3/27,019 controls) and found that three out of five GPHN microdeletions tested for 
inheritance arose as de novo events 13. In this study, we present additional functional 
data elucidating the molecular mechanisms by which the N-terminal GPHN deletions 
cause dysfunctional GABAergic synaptic inhibition and thereby increase susceptibility 
of IGE. 
Molecular characterization demonstrates that the truncated GPHN Δ5-9 variant 
(Family 1) exerts a dominant-negative effect on the structural synaptic organization of 
gephyrin and GABAAR clusters. Gephyrin oligomerization is thought to be a 
concerted interaction mediated by G-domain trimerization 38, G- and E-domain 
interaction 18, E-domain dimerization 25 and C-domain binding to other proteins 
controlled by posttranslational modifications 39. The truncated Δ5-9geph protein itself 
is not able to form clusters and impairs the oligomerization process of regular 
gephyrin (Fig. 4), which can be explained by the loss of the G-domain trimerization 
interface encoded mainly by exon 6 38. Instead, Δ5-9geph probably forms irregular 
dimers by interaction of the intact E-domain with regular gephyrin E-domains 25. 
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Thereby, it stochastically affects oligmerization of regular gephyrin in a dominant-
negative manner. Importantly, the size of remaining gephyrin and GABAAR clusters 
was significantly reduced, which will probably impair the recently described 
homeostatic regulation of gephyrin scaffolds and normal development of the neuronal 
inhibitory GABAergic circuits 40. Consistently with our findings, it was speculated that 
cellular stressors such as elevated temperature or alkalosis, which can arise from 
seizure activity, might induce irregular exon skipping in GPHN mRNA leading to 
deletions within the G- and C-domain thus causing a dominant-negative effect on the 
oligomerization of synaptic gephyrin clusters 20. Moreover, given the constitutional 
expression of the truncated Δ5-9geph protein, it is also likely that during development 
Δ5-9geph expression negatively affects the establishment of certain networks which 
cumulatively contribute to the genetic variance of the IGE phenotype. 
In Family 2, the GPHN Δ2-3 variant causes a frameshift with premature stop codon, 
resulting in a truncated GPHN protein consists of the first 21 amino acids encoded by 
exon 1, followed by seven residues encoded by out of frame codons before the 
premature stop codon (p.V22Gfs*7 – Fig. 1F). Notably, five out of six GPHN multi-
exon deletions (Δ2-5 (n = 2), Δ3-8, Δ3-11 and Δ3-12) reported by Lionel et al. 13 in 
patients with neurodevelopmental disorders result in frameshifts and premature stop 
codons, causing truncated GPHN proteins including the first 21 or 47 amino acids 
encoded by exon 1 or exons 1-2, respectively. Although truncated gephyrins 
comprising the first 47 amino acids have the capacity to impair the oligomerization of 
regular gephyrin 20, the expression of these frameshift-causing GPHN multi-exon 
deletions will probably be negligible due to nonsense-mediated mRNA decay 28. 
Considering the fact that we were able to amplify the GPHN Δ2-3 transcript in cDNA 
derived from blood cells (Supplementary Material Fig. S2), at least a partial 
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expression of the GPHN Δ2-3 transcript is possible. However, we assume that in 
these patients the pathogenic effect of the truncated GPHN results predominantly 
from haplo-insufficiency rather than from effects on the oligomerization of regular 
gephyrin. 
Given the intriguing impact of an impaired GABAergic synaptic transmission in 
epileptogenesis 41, the reduced amount of synaptic GABAARs in the presence of 
truncated gephyrins exerts a functionally convergent effect similar to that observed by 
mutations of genes encoding GABAAR subunits (GABRA1, GABRB3, GABRG2 and 
GABRD) in rare families with dominantly inherited IGE syndromes (for reviews see 
42,43). On molecular level, GABR gene mutations generally lead to a reduced surface 
expression of GABAARs, which results in the reduction of the amplitude of GABA-
evoked currents. Although GPHN deletions also should affect glycine receptor 
clustering, this seems to have no significant pathogenic consequences considering 
that typical symptoms of glycinergic deficits, such as hyperekplexia, are missing.  
Interestingly, in Family 1, the clinically unaffected father as well as the JME-affected 
index patient carrying the GPHN Δ5-9 deletion exhibited an impaired cortical 
inhibition leading to hyperexcitability, as demonstrated by TMS, which mainly reflects 
the functional state of GABAergic interneuronal circuits 44. This imbalance of the 
inhibitory/excitatory ratio corresponds well with the experimentally validated 
dominant-negative effect of the GPHN Δ5-9 deletion on the reduced size and number 
of GABAAR clusters at inhibitory synapses. Moreover, diffusion tensor imaging 
showed a statistically significant increase in the structural connectivity of the mesial 
frontal region and the descending motor circuits in the JME-affected index patient 
and a slightly enhanced connectivity in the father of Family 1. An altered structural 
connectivity of the mesial frontal region has recently been found in JME 45 and may 
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explain the predominant manifestation of myoclonic seizures in the JME-index patient 
of Family 1. Altogether, our present findings add to convergent lines of evidence that 
dysfunctional GABAergic synaptic inhibition represent a key pathogenic process 
shared by a wide spectrum of neurodevelopmental disorders, such as epilepsy, ASD, 
schizophrenia, and intellectual disability 46. Consistently, a high prevalence of 
epilepsy has been found in autism spectrum disorder (ASD), ranging from 21% in 
ASD subjects with an intellectual disability to 8% in those without intellectual disability 
47. Notably, the index patient of Family 1 had a typical JME but also exhibited a broad 
range of psychiatric and behavioral disorders. 
Carriers of GPHN microdeletions encompassing the N-terminal exons display a high 
phenotypic variability and incomplete penetrance, strongly depending on the genetic 
background. This pleiotropic expression has been observed for all microdeletions (at 
1q21.1, 15q11.2, 15q13.3, 16p11.2, 16p13.11, 22q11.2, A2PB1, NRXN1) that have 
been associated with IGE or other neurodevelopmental disorders 48. Most likely, 
these microdeletions impair neurodevelopmental processes in a rather unspecific 
manner and contribute to the genetic variance of a wide spectrum of 
neurodevelopmental disorders. The individual disease phenotype is probably further 
specified by the interplay with genetic background effects and environmental 
influences following an oligo-/polygenic inheritance model with substantial genetic 
heterogeneity 5. In particular, bi-parental genetic risk factors may contribute to the 
epilepsy phenotype of the index subject. Accordingly, segregation analysis in Family 
2 suggests a complex bi-parental inheritance pattern composed by a paternal 
inheritance of the GPHN Δ2-3 deletion and a predominant epileptogenic susceptibility 
factor(s) transmitted by the mother, who had afebrile seizures during infancy. 
Likewise, the brother showing a diploid GPHN copy status had a history of febrile 
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seizures. Similar inheritance patterns were also reported earlier for exonic GPHN 
microdeletions 13 and other recurrent microdeletions increasing risk for IGE 42,43. As 
we did not observe metabolic Moco deficiency symptoms, the hemizygous 
microdeletions of N-terminal GPHN exons presumably affect only the synaptic 
functions of gephyrin. However, it cannot be excluded that minor alterations in the 
Moco-enzymes activity during brain development might contribute to disease 
manifestation.  
In summary, our study strengthens a previous statistical association of GPHN 
microdeletions affecting the gephyrin G-domain with a wide range of neuropsychiatric 
disorders and expands this spectrum to IGE syndromes 13. GPHN microdeletions 
affecting the N-terminal gephyrin domain confer a susceptibility effect with high 
phenotypic variability and incomplete penetrance depending on the genetic 
background. We provide genetic, functional and neurophysiological evidence that 
structural exonic microdeletions affecting the gephyrin G-domain can increase 
neuronal excitability by an impairment of GABAergic synaptic inhibition, and thereby 
confer susceptibility for IGE. 
 
SUPPLEMENTARY DATA 
Further data are provided as Supplementary Material.  
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FIGURE LEGENDS 
Figure 1. Genetic analyses of GPHN microdeletions   
(A) Genomic localization (hg19) and GPHN deletions identified in the IGE index 
patients. The deletion segregating in Family 1 is spanning approximately 129 kb 
involving exons 5-9. The microdeletion of Family 2 is approximately 158 kb in size 
and deletes exons 2-3. (B) Familial segregation of exonic GPHN microdeletions. 
Deletion carriers are indicated by copy number state (CN) = 1, whereas CN = 2 
represents an analyzed individual without deletion; black symbols = affected by IGE; 
TMS path.= increased cortical excitability without seizures; arrows highlight index 
cases. (C) Electropherogram of the cDNA Δ5-9 GPHN transcript sequence of the 
index patient F1II.1 and his father F1I.1, confirming the transcription of a truncated 
Δ5-9 GPHN transcript. Arrow separates the sequence of exon 4 from the fused 
adjacent sequence of exon 10. The exon annotation refers to the genomic 
organization of GPHN (NM_020806.4). (D) Electropherogram of the cDNA Δ2-3 
GPHN transcript sequence of the index patient F2II.2, confirming the transcription of 
a truncated Δ2-3 GPHN transcript (NM_020806.4). Arrow separates the sequence of 
exon 1 from the fused adjacent sequence of exon 4. (E) Schematic structure of 
regular gephyrin and Δ5-9geph with numbering of deleted residues in Δ5-9geph. (F) 
Sequence of the truncated Δ2-3 GPHN transcript expressed by father and son F2II.2. 
Residue Val22 is encoded by a splitted codon composed by exons 1 and 2; the 
GPHN Δ2-3 variant results in a frameshift and a premature stop codon (p.V22Gfs*7, 
NP_001019389.1). 
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Figure 2. Paired-pulse transcranial magnetic stimulation  
The relative variation of the average peak-to-peak amplitude of the motor evoked 
potential in relation to the baseline (set at 100%), is plotted as a percentage, for the 
conditions “intracortical inhibition” (ISI 3 ms), white bars; and “intracortical facilitation” 
(ISI 13 ms), black bars. Both the patient and his father exhibited an increased cortical 
excitability, with decreased ICI and increased ICF, statistically significant compared 
to healthy controls (***P < 0.001, ANOVA).  
 
Figure 3. Δ5-9geph interacts with regular gephyrin and affects oligomerization 
in a dominant-negative manner.  
(A) Morphology and localization of GFP-tagged regular gephyrin and Δ5-9geph in 
cultured hippocampal neurons. Insets show high-magnification of the dendrites. 
Arrowheads point to spine heads, morphological structures of excitatory synapses. 
Scale bar = 20 μm. (B) Myc-tagged gephyrin forms large “blobs” upon expression in 
HEK293 cells, while Δ5-9geph-GFP is diffusively distributed. Upon co-expression, 
Δ5-9geph-GFP dominant negatively affected gephyrin oligomerization leading to 
either completely diffuse regular gephyrin (C1) or the formation of microclusters 
harboring regular and truncated gephyrin-variants (C2). (D) Quantification of gephyrin 
blobs and diffuse gephyrin in 100 cells of each condition derived from three 
independent transfections. (E) Immunoblots of GFP-tagged gephyrin and Δ5-9geph 
expressed in HEK293 cells indicate that the truncated gephyrin is stable and 
expressed at equivalent levels to regular gephyrin. ß-tubulin served as loading 
control. (F) Δ5-9geph-GFP immunoprecipitated with myc-tagged gephyrin in HEK293 
cell-lysates following co-expression of both proteins. 
PUBLICATION: GPHN IN IGE 
44 
Figure 4. GABAergic innervation is decreased upon expression of Δ5-9geph-
GFP  
(A) Schematic structure of gephyrin and the epitope of the rGeph-C antibody, which 
was used to distinguish between endogenous gephyrin and Δ5-9geph. 
Representative dendrites (20 µm) of EGFP- or Δ5-9geph-expressing cultured 
hippocampal neurons (11+2 DIV) immunostained for endogenous gephyrin (B), 
GABAAR γ2 subunit (E) or VGAT (H). (B-G) Δ5-9geph-GFP significantly reduced 
number and size of endogenous gephyrin clusters and GABAA γ2-containing 
receptors. (H-J) Morphology and numbers of spine heads were not affected by Δ5-
9geph-GFP. Arrowheads point to exemplary spines that have been quantified. Scale 
bar = 10 µm. All data are expressed as mean ± SEM (**P < 0.05; ***P < 0.001, 
Student’s t-test; n = 14-18 neurons per condition from two independent preparations). 
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FIGURES 
Figure S1. Genetic analyses (A) Familial segregation of exonic GPHN 
microdeletions. Deletion carriers are indicated by copy number state (cn) = 1, 
whereas cn = 2 represents an analyzed individual without deletion; black symbols = 
affected by IGE; TMS path.= increased cortical excitability without seizures; arrows 
highlight index cases. (B) Genomic localization (hg19) and GPHN deletions identified 
in the IGE index patients. The deletion segregating in Family 1 is spanning 
approximately 129 kb involving exons 5-9. The microdeletion of Family 2 is 
approximately 158 kb in size and deletes exons 2-3. (C) Electropherogram of the 
cDNA Δ5-9 GPHN transcript sequence of the index patient F1II.1 and his father 
F1I.1, confirming the transcription of a truncated Δ5-9 GPHN transcript. Red coloring 
indicates the sequence of exon 4 whereas the sequence of exon 10 is highlighted in 
blue. The exon annotation refers to the genomic organization of GPHN 
(NM_020806.4). (D) Schematic structure of regular gephyrin and Δ5-9geph with 
numbering of deleted residues in Δ5-9geph. (E) Electropherogram of the cDNA Δ2-3 
GPHN transcript sequence of the index patient F2II.2, confirming the transcription of 
a truncated Δ2-3 GPHN transcript (NM_020806.4). Red coloring indicates the 
sequence of exon 4 whereas the sequence of exon 1 is highlighted in blue. (F) 
Sequence of the truncated transcript (see panel E) expressed by father and son 
F2II.2. The arrow highlights the fusion of exon 1 and 4. Residue Val22 is encoded by 
a splitted codon composed by exons 1 and 2; the GPHN Δ2-3 variant results in a 
frameshift and a premature stop codon (p.V22Gfs*7, NP_001019389.1). 
 
Figure S2. Family 1 (GPHN Δ5-9 deletion). Assessment of the copy number state by 
TaqMan qPCR assay located in GPHN exon 7 (Assay ID: Hs01711518_cn; Life 
Technologies, Carlsbad, CA, USA). The copy number state of 1 (CN = 1) indicates a 
hemizygous deletion, whereas a CN = 2 represents the normal diploid CN state.  
 
Figure S3. Blood cell cDNA amplification with primers flanking the GPHN Δ5-9 
deletion in Family 1. Left: Agarose gel electrophoresis illustrates the expression of 
the truncated Δ5-9 GPHN transcript in F1II.1 (index-patient) and F1I.1 (father). Right: 
Analysis of the same cDNA by more sensitive Agilent 2200 TapeStation Nucleic Acid 
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System indicates also the presence of the 793 bps wt transcript in father and patient. 
Targeted band sizes are highlighted by asterisks; green = 793 bps wt transcript; red = 
125 bps truncated Δ5-9 GPHN transcript. 
 
Figure S4. Blood cell cDNA amplification with primers flanking the GPHN Δ2-3 
deletion in Family 2. Using the sensitive Agilent 2200 Tape Station Nucleic Acid 
System, the 544 bps wt transcript of the G-domain is present in all cDNAs analyzed. 
The truncated GPHN Δ2-3 transcript of 407 bps was observed in the father (F2I.1) 
and the index patient (F2II.2).  
 
Figure S5. Diffusion tensor imaging of GPHN Δ5-9 deletion carriers of Family 1. 
Results of the probabilistic tractography from the mesial frontal region in healthy 
controls (blue) compared to the index patient and his father (yellow/orange), overlaid 
on the MNI 152 T1 template image in three orthogonal slices (MNI coordinates given 
in figure). The connectivity reaches beyond the range seen in healthy controls, both 
in the index-patient and his father.  
 
Figure S6. Validation of the rGeph-C antibody. Δ5-9geph was transiently expressed 
in HEK293 cells and immunostained either with the commercial mouse monoclonal 
3B11 antibody (top panels), that binds to the E-domain or rabbit monoclonal antibody 
here termed rGeph-C (lower panels), whose epitope lies within the C-domain that is 
deleted in Δ5-9geph. The antibody only recognizes endogenous gephyrin but not Δ5-
9geph. Scale bar = 25 μm. 
 
Figure S7. Representative images of cultured hippocampal neurons expressing either 
EGFP or Δ5-9geph. Framed dendritic segments are shown at higher magnification in 
Figure 3. Scale bar = 20 µm. 
 
Figure S8. Urinary metabolite analysis of samples derived from the patient (P), his 
mother (M) and father (F), control and Moco deficient individuals (MoCD), who were 
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previously diagnosed (1). All concentrations of metabolites were normalized to 
creatinine concentration in urine samples. 
 
Figure S9. Genomic localization (hg19) of the GPHN microdeletions identified in the 
IGE index-patients in this study (dark grey) and six patients with autism, 
schizophrenia and seizures recently reported by Lionel et al. (light gray) (2). 
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MATERIALS AND METHODS  
Exome sequencing 
Sequence analysis of the whole exome was performed in the IGE proband and both 
parents using next generation sequencing techniques as described previously (3). 
The exome data had an average coverage >30x for 78-79% of the exome target 
sequences. The GPHN gene an average coverage of 49-55x with a minimal 
coverage for an exon of 16x (ENST00000478722, NM_020806.4). Variants were 
filtered for high-quality novel GPHN variants compared to an in-house variation 
database (>400 exomes, dbSNP build 135 (www.ncbi.nlm.nih.gov/projects/SNP/), 
1000Genomes database (www.1000genomes.org/) and the Exome Variant Server 
(http://evs.gs.washington.edu/EVS/). 
 
Diffusion tensor imaging  
Data was acquired in Family 1 for the index-patient, his father and 15 healthy controls 
with no personal history of seizures or other neurological disorders and no 
medication (7 female, mean age 34 years, range 22-54 years). The mother could not 
tolerate any MRI studies due to claustrophobia. Images were recorded on a 3T GE 
Excite HDx scanner using an acquisition scheme with 64 diffusion weighted 
directions (b-value 1,000 s/mm²) and one B0 image with a slice thickness of 2.4 mm 
and 96 x 96 voxels in plane resolution, a TE of 87 ms and TR of 16,000 ms. Images 
were processed using FSL 4.1.9 software (www.fmrib.ox.uk), estimating a two fibre 
per voxel model. Probabilistic tractography was performed as recently described (4) 
seeding from a region of interest (ROI) in the left mesial frontal lobe and normalizing 
the resulting tracts to a common acquisition specific template in MNI space. 
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3.2 Publications on RE  
3.2.1 RBFOX genes in RE (published) 
Lal D, Reinthaler EM, Altmüller J, Toliat MR, Thiele H, et al. (2013) RBFOX1 and RBFOX3 
Mutations in Rolandic Epilepsy. PLoS ONE 8: e73323. doi:10.1371/journal.pone.0073323. 
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Figure S1  Raw SNP intensity data of all samples carrying exon-disrupting microdeletions 
affecting the RBFOX1 and RBFOX3 genes 
RBFOX1 365 kb deletion 
 
RBFOX3 43 kb deletion 
 
Figure S2  Flanking sequence information for RBFOX1 variant p.A299_A300del 
(c.893_898delCTGCCG, p.A299_A300del, NM_001142333) 
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Figure S3  Multiple Sequence AlignmentRBFOX1 variant A299_A300del (c.893_898delCTGCCG; 
NM_001142333) 
 
Table S1. RBFOX1and RBFOX3 exonic sequence variants  
 
 
Start End Type HGNC CCDS Consequence MutCDNA MutProt Patient 
16 7703830 7703836 INDEL RBFOX1 CCDS55984.1 FRAMESHIFT c.690_696delGTATCCAins(GTATCCA)2 p.A233Vfs*74 EG1208 
16 7703830 7703836 INDEL RBFOX1 CCDS55983.1 FRAMESHIFT c.771_777delGTATCCAins(GTATCCA)2 p.A260Vfs*74 EG1208 
16 7703830 7703836 INDEL RBFOX1 CCDS55983.1 FRAMESHIFT c.771_777delGTATCCAins(GTATCCA)2 p.A260Vfs*74 EG1208 
16 7703830 7703836 INDEL RBFOX1 CCDS10531.1 FRAMESHIFT c.831_837delGTATCCAins(GTATCCA)2 p.A280Vfs*51 EG1208 
16 7703830 7703836 INDEL RBFOX1 CCDS45405.1 FRAMESHIFT c.831_837delGTATCCAins(GTATCCA)2 p.A280Vfs*51 EG1208 
16 7703830 7703836 INDEL RBFOX1 CCDS10532.1 FRAMESHIFT c.831_837delGTATCCAins(GTATCCA)2 p.A280Vfs*51 EG1208 
16 7726819 7726824 DEL RBFOX1 CCDS10531.1 DELETION c.1037_1042delCTGCCG p.A347_A348del E699 
16 7726819 7726824 DEL RBFOX1 CCDS55984.1 DELETION c.893_898delCTGCCG p.A299_A300del E699 
16 7726819 7726824 DEL RBFOX1 CCDS55983.1 DELETION c.974_979delCTGCCG p.A326_A327del E699 
16 7726819 7726824 DEL RBFOX1 CCDS45405.1 DELETION c.1037_1042delCTGCCG p.A347_A348del E699 
16 7726819 7726824 DEL RBFOX1 CCDS10532.1 DELETION c.1037_1042delCTGCCG p.A347_A348del E699 
16 7726819 7726824 DEL RBFOX1 CCDS55983.1 DELETION c.974_979delCTGCCG p.A326_A327del E699 
17 77090608 77090608 SNP RBFOX3 CCDS45805.1 STOP_GAINED c.861C>A p.Y287* E136 
 
Hg19, detailed description of variants identified in RBFOX1 and RBFOX3 
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3.2.2 GRIN2A in RE (published) 
Lemke JR*, Lal D*, Reinthaler EM*, Steiner I, Nothnagel M, et al. (2013) Mutations in GRIN2A 
cause idiopathic focal epilepsy with rolandic spikes. Nat Genet 45: 1067–1072. doi:10.1038/ng.2728. 
*These authors contributed equally to this work 
PUBLICATION: GRIN2A IN RE 
77 
 
PUBLICATION: GRIN2A IN RE 
78 
PUBLICATION: GRIN2A IN RE 
79 
PUBLICATION: GRIN2A IN RE 
80 
 
PUBLICATION: GRIN2A IN RE 
81 
 
PUBLICATION: GRIN2A IN RE 
82 
 
PUBLICATION: GRIN2A IN RE 
83 
 
PUBLICATION: GRIN2A IN RE 
84 
 
PUBLICATION: GRIN2A IN RE 
85 
PUBLICATION: GRIN2A IN RE 
86 
PUBLICATION: GRIN2A IN RE 
87 
PUBLICATION: GRIN2A IN RE 
88 
PUBLICATION: GRIN2A IN RE 
89 
PUBLICATION: GRIN2A IN RE 
90 
PUBLICATION: GRIN2A IN RE 
91 
PUBLICATION: GRIN2A IN RE 
92 
PUBLICATION: GRIN2A IN RE 
93 
PUBLICATION: GRIN2A IN RE 
94 
PUBLICATION: GRIN2A IN RE 
95 
PUBLICATION: GRIN2A IN RE 
96 
PUBLICATION: GRIN2A IN RE 
97 
PUBLICATION: GRIN2A IN RE 
98 
PUBLICATION: GRIN2A IN RE 
99 
PUBLICATION: GRIN2A IN RE 
100 
PUBLICATION: 16p11.2 DUP IN RE 
101 
3.2.3 16p11.2 duplications in RE (submitted; revised manuscript) 
Reinthaler EM*, Lal D*, Reymond A, Jacquemont et al. 16p11.2 duplications confer risk for 
typical and atypical Rolandic epilepsy. BRAIN 
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Abstract 
Rolandic Epilepsy is the most common idiopathic focal childhood epilepsy. Its 
molecular basis is largely unknown though a complex genetic etiology is generally 
assumed. We demonstrate that genomic duplications between breakpoints 4 and 5 
at the 16p11.2 locus, previously associated with neurodevelopmental disorders, are 
also associated with typical and atypical Rolandic epilepsy. In a cohort of 393 
patients, we identified five patients with the typical recurrent 600 kb (29.5-30.1Mb) 
duplication and a sixth case with an atypical shorter rearrangement (in total 1.53%). 
This differed significantly from the prevalence observed in the general population of 
European origin [32/62403; (0.05%) Fisher’s exact test P = 1.4 x 10-7, OR = 30.2, 
95% CI: 10.3-73.9]. The duplication is not associated with all forms of epilepsies, as 
none was detected in 330 and 1408 patients with either temporal lobe epilepsy or 
genetic generalized epilepsies, respectively. In a subsequent screen among 
children carrying the 16p11.2 600 kb rearrangement we identified three patients in 
117 duplication carriers (2.6%) but none in 202 carriers of the reciprocal deletion. 
The 16p11.2 duplication is the second recurrent structural variant after GRIN2A 
mutations and deletions identified for typical and atypical Rolandic epilepsy. 
 
 
Keywords: rolandic epilepsy; microduplications; 16p11.2; genetics 
Abbreviations: RE= rolandic epilepsy; ARE= atypical rolandic epilepsy; CTS= 
centrotemporal spikes; CNV= copy number variation; SNP= single nucleotide 
polymorphism 
 




Rolandic epilepsy (RE), also known as benign epilepsy with centrotemporal spikes 
(BECTS), is the most common childhood epilepsy with a prevalence of 0.2 – 
0.73/1000 (i.e. about 1/2500) (Beilmann et al., 1999; Sidenvall et al., 1996; Waaler 
et al., 2000). RE is related to rarer, and less benign epilepsy syndromes, including 
atypical benign partial epilepsy (ABPE), Landau-Kleffner syndrome (LKS) and 
epileptic encephalopathy with continuous spike-and-waves during sleep (CSWSS) 
(Doose et al., 2001; Gobbi et al., 2006; Guerrini and Pellacani, 2012; Hahn et al., 
2001), referred to as RE related syndromes, or atypical Rolandic epilepsy (ARE) by 
some authors (Fejerman, 2009). RE and ARE share blunt, high-voltage, 
characteristically shaped centrotemporal spikes (CTS) of characteristic morphology 
in the EEG. In ARE spikes become generalized during slow wave sleep, 
morphology, location and background activity may vary to some extend (Doose et 
al., 2001; Fejerman, 2009). The CTS EEG trait is not entirely specific to RE, as it is 
also found in 2-4% of healthy children (Eeg-Olofsson et al., 1971; Okubo et al., 
1994), in 10-28% of children with autism spectrum disorder (ASD) (Chez et al., 
2006; Lewine et al., 1999; Tuchman and Rapin, 1997) and in the Fragile-X-
Syndrome (Musumeci et al., 1991; Musumeci et al., 1999). RE is further 
characterized by focal (perioral sensorimotor) seizures and secondarily generalized 
seizures, which resolve spontaneously during adolescence. ARE denote more 
severe forms of focal childhood epilepsies with various additional seizure types, 
developmental language delay or regression, speech dyspraxia and variable 
neuropsychiatric deficits (Gobbi et al., 2006; Hughes, 2011). 
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The underlying etiologies of RE remain largely unknown although a genetic basis 
has been postulated. Multiplex family studies have suggested an autosomal 
dominant inheritance of the EEG trait CTS (Bali et al., 2007; Heijbel et al., 1975). 
However several other arguments, amongst them the distribution of seizure-risk in 
relatives of patients with RE, argue for a complex mode of inheritance (Vears et al., 
2012). Linkage studies identified loci for CTS on 15q14 (LOD 3.56) and 11p13 (LOD 
4.30) (Neubauer et al., 1998; Strug et al., 2009). Fine mapping of the latter locus 
revealed an association with the ELP4 gene, but causative mutations have not yet 
been identified (Strug et al., 2009). Markers linked to chromosome 16p12-11.2 
(LOD 3.68) were found in one family affected by RE with paroxysmal exercise-
induced dystonia and writer’s cramp (Guerrini et al., 1999), while disease-
associated variants in the SRPX2 gene were found in a family with X-linked rolandic 
epilepsy, oral and speech dyspraxia and intellectual disability and in one patient 
with perisylvian polymicrogyria and rolandic seizures (Roll et al., 2006). Rare 
variants in KCNQ2 and KCNQ3 were identified in a small number of patients with 
RE (Neubauer et al., 2008). Very recently it was shown that mutations in GRIN2A 
are major genetic risk factors for idiopathic focal epilepsies with CTS, with and 
without language dysfunction (Carvill et al., 2013; Lemke et al., 2013; Lesca et al., 
2013). 
Copy number variants (CNV) are an important source of structural genomic 
variation. Whereas many CNVs, especially non-recurrent ones, are not necessarily 
related to a clinical phenotype, six prominent recurrent CNVs (1q21, 15q11.2, 
15q13.3, 16p11.2, 16p13.11 and 22q11.2) are strongly associated with seizures 
and a range of neurodevelopmental and neuropsychiatric disorders including autism 
(Cook and Scherer, 2008; Cooper et al., 2011; de Kovel et al., 2010; Helbig et al., 
2009; Sebat et al., 2007; Stefansson et al., 2008). One of the characteristic features 
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of these recurrent CNVs is their remarkable phenotypic variability suggesting a 
shared genetic basis of the above diseases. The 16p11.2 600 kb BP4-BP5 
microdeletion (OMIM #611913) is associated with ASD, obesity and intellectual 
disability with and without epilepsy, whereas the reciprocal duplication (OMIM 
#614671) is linked to schizophrenia, microcephaly, intellectual disability and being 
underweight (Bijlsma et al., 2009; Jacquemont et al., 2011; McCarthy et al., 2009; 
Shinawi et al., 2010; Walters et al., 2010; Weiss et al., 2008; Zufferey et al., 2012). 
Recurrent microdeletions at 15q11.2, 15q13.3 and 16p13.11 have been identified 
as important risk factors for genetic generalized epilepsy (GGE) accounting for 
about 1% of these patients but are also associated with a range of other 
neuropsychiatric symptoms (de Kovel et al., 2010; Dibbens et al., 2009; Helbig et 
al., 2009). These pleiotropic effects and the associations between recurrent CNVs 
and GGE prompted us to investigate the frequency of these six recurrent CNVs and 
novel large CNVs in a cohort of children with RE or ARE.  
 
Subjects and Methods 
Study participants 
In a multi-centre effort RE/ARE patients were recruited from Germany, Austria, 
Canada and Australia. 98 of the patients were ascertained via multiplex-families 
with the minimum criteria of at least two affected siblings. The index case had to be 
diagnosed with RE or ARE, and the affected sibling(s) either with RE, ARE, or the 
EEG trait only. All other 183 RE/ARE were patients recruited consecutively at the 
participating clinics, as soon as the diagnosis of RE/ARE was present, irrespective 
of their family history for seizures. Diagnosis of RE was performed according to the 
International Classification of Seizures and Epilepsies (Berg et al., 2010). The 
various related types of atypical Rolandic epilepsy were diagnosed as specified 
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previously (Aicardi and Chevrie, 1982; Doose et al., 2001; Hahn et al., 2001). The 
discovery set included a total of 281 unrelated patients of Caucasian ancestry 
affected by RE (n = 230) and ARE (n = 51) (165 males and 116 females), and 1512 
platform matched, unscreened German population controls (755 males and 757 
females). The replication cohort consisted of 112 cases with RE (n = 109) and ARE 
(n = 3) (63 males and 49 females), from Australia (n = 78) and Austria (n = 34) 
ascertained with the diagnosis of RE/ARE irrespective of whether they have a family 
history of seizures. Additional SNP-array data were obtained from 1408 genetic 
generalized epilepsy (GGE) patients, 330 mesial temporal lobe epilepsy (mTLE) 
patients and 2256 German population controls (KORA: n =  1250, POGEN: n= 
1006). We also studied 319 children carrying a 600kb 16p11.2 rearrangement. 
These patients were assembled by screening neurodevelopmental disorders 
cohorts through a network of cytogenetic centers (Jacquemont et al., 2011; Zufferey 
et al., 2012). For summarized description of all cohorts see Supplementary Table 1. 
Written informed consent was obtained from all participating patients and, when 
appropriate, from both parents and adolescents. This study was approved by all 
respective local institutional review boards.  
 
Genotyping, copy number variation detection and validation 
CNVs were detected by high-density SNP genotyping arrays (Illumina 
HumanOmniExpress BeadChip) and subsequent CNV calling was carried out with 
the PennCNV software (Wang et al., 2007). CNVs were considered to match 
published recurrent CNVs if they overlapped at least 80% of the respective CNV-
length. All called recurrent candidate CNVs were more than 350 kb in size and 
covered with 100 - 756 consecutive SNP-probes. Smaller CNVs of at least 50 kb 
nested within the recurrent candidate regions were considered if they included one 
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of the previously proposed candidate genes (de Kovel et al., 2010; Dibbens et al., 
2009). Genome-wide CNV screening beyond the six candidate regions was 
restricted to CNVs with a segment size > 500 kb (Nicoletti et al., 2012) and a 
minimum of 50 markers to achieve a high accuracy and reproducibility of CNV 
callings across different array platforms, laboratory sites and calling algorithms 
(Pinto et al., 2011). CNVs were manually inspected in the Illumina Genome Viewer 
Software for the regional SNP heterozygosity state (BAF) and log2 ratios of the 
signal intensities (LRR). 1512 controls genotyped on 
IlluminaHumanOmniExpressBeadChip and 330 mTLE patients genotyped on 
IlluminaHap550 array were analyzed with PennCNV. Regions of CNVs detected in 
patients were manually inspected in the control samples for the presence of 
duplications and deletions. CNV calling for samples genotyped on Affymetrix 6.0 
array were performed as previously reported (de Kovel et al., 2010; Lal et al., 2013). 
Recurrent CNV validation and segregation in families was performed with real-time 
quantitative PCR (qPCR) using TaqMan CNV probes (Supplementary Table 2; Life 
Technologies, Darmstadt, Germany) and custom array-CGH for the 16p11.2 
duplication (Agilent Technologies, Santa Clara, CA). This custom array contains 
about 544 probes in the 16p11.2 region (chr16:29,500,000-30,200,000, hg19) with 




In our discovery cohort we identified CNVs at four of the six investigated recurrent 
candidate loci (15q11.2, 15q13.3, 16p11.2 and 22q11.2) (Table 1) as well as other 
CNVs (Table 2). We found a significant enrichment of 16p11.2 duplications in 
RE/ARE patients when compared with controls. Four out of 281 patients (1.42%) 
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carried a ~600 kb 16p11.2 microduplication compared to only one in 1512 controls 
(0.07%) [Fisher´s exact test, P =0.0026, OR = 21.8; 95% CI: 2.14-1068.36] (Table 
1). We identified one additional patient with a smaller partial duplication 
(approximately 110kb of unique sequence; hg19 chr16:29,650,000-29,760,000). 
This atypical rearrangement starts at BP4 and encompasses the genes SPN, 
QPRT, and C16orf54 within the unique sequence (Supplementary Fig. 1). Of note, 
we identified one additional individual carrying the classical 16p11.2 duplication. He 
was screened with the initial discovery cohort, but was finally not included as not all 
inclusion criteria were met (suspected focal cortical dysplasia). All six tentative 
16p11.2 duplications, including the one later removed due to the uncertain MRI 
result, were validated by Taqman quantitative real-time PCR and custom array-
CGH. We established the breakpoint boundaries at the classical BP4 and BP5 
hotspots (Zufferey et al., 2012) in all five 600 kb sized typical 16p11.2 duplications. 
To confirm our findings we subsequently screened the 16p11.2 locus in an 
independent replication cohort of 112 patients with RE/ARE. This screen revealed 
one further classical recurrent 600 kb-microduplication (0.89%) (Fig. 1) which could 
be validated by qPCR.  
We also identified a nominally significant increase of duplications at the 15q11.2 
locus (approximate genomic coordinates according to hg19 22,750,000-23,350,000) 
in our discovery cohort. Six patients displayed the duplication in comparison to 8 out 
of 1512 controls [Fisher´s exact test, P = 0.014, OR =4.1; 95% CI: 1.16-13.59]. This 
borderline association did not remain significant after Bonferroni correction for 
multiple comparisons.  
To validate the previously reported prevalence of 16p11.2 duplications among the 
general population we examined array data from an additional cohort of 2256 
healthy individuals from Germany (KORA, PopGen) unscreened for epilepsy (Lal et 
PUBLICATION: 16p11.2 DUP IN RE 
111 
al., 2013) but did not detect any new 16p11.2 duplications or deletions. This is in 
accordance with previous work setting the prevalence of the duplication at 0.05% in 
the European population (31 duplications out of 58,635 tested individuals) 
(Jacquemont et al., 2011). In a joint analysis of the discovery and replication cohorts 
with both control cohorts, 16p11.2 duplications were seen at a frequency of 1.3 % 
among patients and were thus significantly associated with RE/ARE [5/393 cases 
vs. 1/3768 controls, Fisher´s exact test, P = 4.1x10-5 OR = 48.4, 95% CI: 5.40-
2264.08]. Inclusion of the atypical duplication at the 16p11.2 locus further increased 
the significance of this association [P =4.42x10-6 OR= 58.27].  
To explore whether the 16p11.2 duplication is a general genetic risk factor for 
common epilepsies, we screened 1408 European patients affected by GGE and 
330 German patients diagnosed with mesial temporal lobe epilepsy (mTLE) for 
16p11.2 duplications using high-density SNP arrays, but detected none.  
 
Clinical data and segregation analysis 
Patients harboring the 16p11.2 duplication either suffered from typical RE (n = 5) or 
atypical RE (n = 1) (Table 3). Three patients (F1-II.1, F3-II.1, F5-II.1) had in addition 
a history of febrile seizures, which can be expected in about 20% of children with 
RE or ARE (Doose et al., 1997). All patients diagnosed with typical RE showed 
normal development and their neuropsychological assessments fell within the 
normal range. Only patient F1-II.1, diagnosed with ARE/LKS, presented with severe 
developmental delay. For individuals F3-II.1 and F6-I.1 calculations of the Body 
Mass Index (BMI) were possible, revealing severely to moderately reduced BMIs 
(F3-II.1: 13.31; F6-I.1: 18.6) consistent with previous reports (Jacquemont et al., 
2011). No data were available on the BMIs of the remaining duplication carriers and 
on head circumferences of all patients. Duplications were inherited in all four cases 
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where testing was possible (Fig. 2) with a maternal transmission in three of them. 
The smaller atypical duplication was inherited from the father who himself had a 
history of febrile seizures (Family 5). While the classical duplication co-segregated 
with RE in one family (Family 2), two other families displayed reduced penetrance 
with reportedly unaffected mothers carrying the duplication (F1-I.2 and F4-I.2). We 
could not determine whether these mothers did exhibit RE-characteristic EEG trait 
during their childhood. Family 1 is interesting as it demonstrates the variability of the 
phenotypes in the duplication carriers, as the index case (F1-II.1) was affected by 
severe ARE/LKS, while his younger sister only displayed CTS in EEG (F1-II.3). 
Notably, the third sibling in this family (F1-II.2) presented the EEG trait without being 
a duplication carrier (Fig. 2). This family is not only affected by the 16p11.2 
duplication but also recently reported carrying a novel p.C231Y GRIN2A mutation 
(Lemke et al., 2013). Whereas the GRIN2A variation segregates with the CTS trait, 
the 16p11.2 duplication seems not to be necessary for the electroclinical component 
of the phenotype. In Family 4, we detected in addition to the 16p11.2 duplication a 
novel missense variation of unknown significance in the DEPDC5, a gene which 
was recently identified in focal epilepsies (Dibbens et al., 2013; Ishida et al., 2013). 
In this family the 16p11.2 duplication was inherited from the unaffected mother and 
the DEPDC5 variant from the unaffected father, resulting in a mutational load in the 
child. Which of those two or if both genetic alterations synergistically contribute to 
the phenotype is not known. 
 
Genotype-phenotype correlations in the 16p11.2 rearrangement cohort 
To further specify the association between RE/ARE and 16p11.2 duplications, we 
examined a large cohort of 319 children (≤18yrs) with 600 kb BP4-BP5 
rearrangements (202 deletions and 117 duplication carriers) from the 16p11.2 
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European consortium. We detected an equal rate of 18% of patients with epilepsies 
(combining unspecified, focal, generalized epilepsies and infantile spasms) among 
the duplication carriers (n=22/117) and deletion carriers (n=37/202) (Supplementary 
Table 3). In the duplication group, three individuals were diagnosed with RE/ARE 
(Supplementary Table 4). One patient presented with typical RE (short nocturnal 
motor facial seizures and centro-temporal spikes activated by sleep). He also 
suffered from reading and spelling difficulties and was diagnosed with an attention 
deficit disorder. The second patient displayed the same electro-clinical features but, 
in addition, also presented with a delay of language, a behavioral disorder, a 
borderline IQ (75) and an early age of onset (2 years of age). He was therefore 
diagnosed as atypical RE. The third patient displayed an ARE-epileptic 
encephalopathy (initially CSWSS, but eventually language regression and ASD 
traits which led to the diagnosis of LKS). An additional (fourth) patient had only CTS 
activated by sleep without seizures. In the deletion group, a single patient had CTS 
activated by sleep without seizures but none suffered from RE/ARE. Hence 
RE/ARE occurred only in duplication carriers (2.6% n=3/117) but not in deletion 
carriers (n=0/202) [Fisher´s exact test, P = 0.05]. Although it was not possible to 
assess the exact prevalence of RE/ARE in the complete cohorts screened (i.e. 
including cases without 16p11.2 rearrangements), we note that RE/ARE features 
are enriched approximately 30-fold in the 16p11.2 duplication cohort as compared 
to the general population given an RE-prevalence of 0.05% (Jacquemont et al., 
2011).  
Other structural rearrangements 
To investigate whether other large CNVs beyond the above six candidate regions 
were present in our RE/ARE patients we performed a genome-wide screen for 
CNVs larger than 500 kb in all 281 individuals of the discovery cohort. In particular, 
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we were interested whether 16p11.2 duplication carriers might display additional 
large CNVs. We found 23 additional CNVs in the 281 RE/ARE patients screened 
(Table 2). Six of these CNVs were partially overlapping with CNVs previously 
reported in patients with epilepsy (Heinzen et al., 2010; Lesca et al., 2012; Mefford 
et al., 2007; Mefford et al., 2010; Mefford et al., 2011; Valvo et al., 2012). With the 
exception of one duplication mapping to chromosome 12q24.33, which was 
identified in two patients and in two out of 1512 controls from the discovery cohort, 
all other CNVs occur as single events in our patient dataset. Interestingly, in one 
16p11.2 duplication carrier (F3-II.1) we identified a second large duplication 
(1.03Mb) on chromosome 22q11.21. Of note, this duplication is shorter than the 
recurrent 22q11.21 duplication which is 3 MB in size (OMIM #608363) and it does 
not include the proposed candidate gene COMT. 
 
Discussion 
In summary, we report a highly significant association of the recurrent 16p11.2 
microduplication with RE/ARE spectrum epilepsies. We detected the 16p11.2 
duplication in 1.53% of RE-patients (six individuals including the smaller atypical 
rearrangement), which equals a more than 30-fold enrichment when compared to 
the prevalence in the general population (0.05%) (Jacquemont et al., 2011).  
 
Our cohorts partly included patients that were required to have a positive family 
history for RE/ARE or the EEG trait as an entry criterion (98 of 393 patients). As 
inherited genetic factors might be enriched in cases with a familial background a 
multiplex pedigree ascertainment method might lead to an overestimation of the 
frequency of such variants in the overall patient population. However, we believe 
that the bias in this study was small as the majority of patients (75%) were enrolled 
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irrespective of their family history and because the frequency of the duplication 
carriers was similar in the multiplex and singly ascertained cohorts (4/295 and 2/98 
respectively). However, this potential sampling bias does not play a role for our 
conclusion that the 16p11.2 is a susceptibility factor for RE because sampling of 
unrelated cases with a positive family history has no influence on the expected 
prevalence of the 16p11.2 duplication in the patient cohort under the assumption of 
the alternative null hypothesis. 
Although the effect size appears considerable the penetrance is incomplete as 
illustrated by the presence of clinically apparently unaffected duplication carriers in 
our families (with the caveat that mild childhood phenotypes might have been 
missed or not reported in the adult carriers). Likewise, the severity and expressivity 
of the phenotypes varied considerably between affected members of the same 
family. Similar observations have been made with other CNVs that are nevertheless 
firmly established as risk factors for epilepsies (de Kovel et al., 2010).  
One remarkable feature of the 16p11.2 rearrangements is the wide diversity of the 
associated phenotypes. The BP4-BP5 duplication and its reciprocal deletion were 
previously associated with schizophrenia/autism, micro-/macrocephaly and 
underweight/obesity mirror phenotypes as well as impairment in cognitive 
performance (Jacquemont et al., 2011; McCarthy et al., 2009; Shinawi et al., 2010; 
Walters et al., 2010; Weiss et al., 2008). In this present report we extend the list of 
neurodevelopmental disorders associated with the recurrent 16p11.2 CNV even 
further to the full spectrum of the RE/ARE phenotype ranging from mild RE cases to 
severe forms of ARE with epileptic encephalopathies. Fitting with clinical 
observations which have long suggested a shared etiology between RE and a 
whole host of other neuropsychiatric syndromes and symptoms [e.g. cognitive 
deficits, language disorders, autism, ADHD (Clarke et al., 2007; Danielsson and 
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Petermann, 2009; Kavros et al., 2008; Tovia et al., 2011) we have identified the 
16p.11.2 duplication as one shared genetic susceptibility factor. In light of the 
phenotypic variability in two families additional modulating genetic variants are 
already identified and further are expected and will be the focus of future research.  
 
The 600 kb long chromosomal region between BP4 and BP5 on 16p11.2 contains 
29 genes (Fig. 1). Most of these genes are expressed in the brain and might thus 
contribute singly or jointly to the etiology of RE and related disorders. Several 
studies on model organisms have attempted to narrow down the dosage sensitive 
genes for the observed brain-related traits. Haploinsufficiency of ALDOA and KIF22 
have been related to change in brain morphology in zebrafish (Blaker-Lee et al., 
2012), while alterations in head size anticorrelated with levels of KCDT13, MAPK3 
and MVP in teleosts and rodents (Golzio et al., 2012). One particularly interesting 
candidate is the PRRT2 gene with a putative role in synaptic vesicle functioning, as 
it has been associated with a range of different childhood epilepsies. Mutations in 
PRRT2 are, for instance, the main cause of benign familial infantile seizures (BFIS) 
and other infantile epilepsy syndromes as well as paroxysmal kinesigenic 
dyskinesia (Chen et al., 2011; Heron et al., 2012; Schubert et al., 2012; Wang et al., 
2011; Wood, 2012).  
Although atypical CNVs in the 16p11.2 interval are rare they are valuable in 
narrowing down the critical genomic interval. We detected one partial 110 kb 
duplication excluding PRRT2 but encompassing SPN, QPRT and C16orf54 in a 
patient who suffered from RE. The QPRT gene is of interest as it encodes an 
enzyme (quinolinate phosphoribosyltransferase), which converts quinolinic acid to 
NAD+ and thus detoxifies this excitotoxic compound (Foster and Schwarcz, 1985; 
Schwarcz et al., 2012). Intracerebral injection of quinolinic acid causes seizures in 
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mice (Lapin, 1978; Vezzani et al., 1989) and elevation of quinolinate levels in the 
human brain is associated with neurodegenerative disorders (Nemeth et al., 2005; 
Vamos et al., 2009). While dosage differences in QPRT might explain the observed 
phenotype, this single, isolated rearrangement does not allow us to draw any firm 
conclusions, especially as we do not have any information on the CTS status of the 
single previously reported additional individual, who carried a partially overlapping 
136 kb duplication, encompassing the QPRT gene (Jacquemont et al., 2011). 
Of interest, the detected borderline association of the 15q11.2 duplication with 
RE/ARE is supported when the comparison is made with its previously reported 
frequency in the general population (Cooper et al., 2011) [6/281 cases vs. 
44/9841controls, Fisher´s exact test, P = 0.0025]. Hopefully these findings will 
encourage further studies on larger RE/ARE cohorts to assess whether the 15q11.2 
duplication really confers any risk to RE/ARE. 
 
In conclusion, we have identified the 16p11.2 duplication as an important genetic 
risk factor for RE/ARE with 1.53 % of patients carrying the variation. Our results 
suggest that the 16p11.2 duplication confers susceptibility mainly for RE/ARE but 
not for other common epilepsy syndromes, such as GGEs or TLE. However, one 
reservation that has to be made is that due to the ascertainment method our cohort 
was biased towards patients with a positive family history and a more severe 
phenotype. To a certain extent this limits conclusions on the exact frequency of the 
duplication and its distribution within the RE/ARE disease spectrum. Another open 
question that remains to be further clarified is the nature of the additional 
phenotypes associated with the duplication in patients with RE/ARE. And finally, an 
interesting but unresolved point concerns the role of additional genetic factors 
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modulating the penetrance and the variable clinical features of the disease. Future 
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Figure 1 16p11.2 duplications  
GRCh37/hg19 region on chromosome 16p11.2. The extent of the BP4-BP5 16p11.2 
duplications found in the discovery cohort is compared with that of the small atypical 
duplication. The duplication is flanked by low-copy repeat segmental duplications 
depicted by yellow, orange and greys bars. Note that only the unique sequences of 
the duplications are shown.  
 
Figure 2 Pedigrees of 16p11.2 microduplication carriers  
Familial segregation of 16p11.2 microduplications. Index cases are depicted by the 
letter “P” and an arrow. Individuals diagnosed with RE/ARE, Centrotemporal spikes 
(CTS) and Febrile seizures (FS) are represented as filled black symbols, unaffected 
family members are indicated by open symbols. Question marks denote unaffected 
family members in whom a possible EEG-phenotype in childhood cannot be 
excluded; RE, Rolandic Epilepsy; ARE, Atypical Rolandic Epilepsy;  
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DEL 1 GGRE14 RE 0  - n.s.  





















 n.s.  
16p11.2 29.5-
30.1 






1 21.8 0.0026* 0.03* 
16p13.11 14.8-
16.4 
DEL 0   2 - n.s.  
  DUP 0    1 - n.s.  
22q11.2 19.1-
22.2 
DUP 1 AVRE04 RE  0 - n.s.  
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Table 1 Legend 
Table 1 Recurrent candidate microdeletions/microduplications in the discovery 
cohort 
a approximate genomic coordinate according to hg19 
b corrected for 12 comparisons (for six loci with two CNV states each) 
c deletion is greater than the classical recurrent 1.4Mb deletion 
d duplications are smaller (~ 430 kb) than the classical recurrent 1.4 Mb duplication 
but encompass the CHRNA7 gene  
Abbreviations: ARE: atypical Rolandic Epilepsy, RE: Rolandic Epilepsy,  
n.s. = not significant 
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Table 2 Heterozygous CNVs greater than 500kb in 281 RE/ARE patients 




























dup None 0  
GGRE01 Male 1p36.32 Chr1:4529544-
5043734 
514 del AJAP1, 
BC037321 
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del AK090620  0  
GGRE03 Male 2p22.3 Chr2:32659489
-33235324 











































AVRE03 Male 5p15.2 Chr5:12543792
-13312470 












546 del RIOK2 0 (Heinzen et 
al., 2010) 
AVRE04 Male 7p11.2 Chr7:57256128
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GGRE11 Male 16q12.1 Chr16:4888917 580 dup CBLN1, 0  
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2012) 














592 dup BC033837 0  












a Start and end positions of the CNVs were assessed with PennCNV.  
b Genes are based by PennCNV-boundaries and ENSEMBL database. Genes which are 
partially affected are included.  
c CNV overlaps partly with CNV previously reported in epilepsy CNV studies. Reference is 
given when CNVs are from the same type. 
d CNV overlaps with hotspot but does not contain the proposed candidate gene  
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Table 3 Individuals with 16p11.2 duplication and electro-clinical features 
Clinical characteristics of 16p11.2 duplication carrier. RE: Rolandic Epilepsy, ABPE: 
Atypical benign partial epilepsy of childhood, FS: Febrile seizures, TCS: Tonic clonic 
seizures, ESES: Electrical status epilepticus during slow sleep, CTS: Centrotemporal 
spikes LKS: Landau-Kleffner syndrome 



















Supplementary Fig. 1 GRCh36/hg18 region on chromosome 16p11.2. Green box 
highlights genomic region of the atypical CNV detected in patient F5-II.1 inherited by 
her father F5-I.1. The CNV covers the genes SPN, QPRT and C16orf54 but not the 
epilepsy associated gene PRRT2.  
  




Supplementary Table 1 Summary of the Samples Used in This Study 





 281 162/116 IlluminaHumanOmniExpr
essExomeBeadChip 
 RE 230   
 ARE 51   
German inhouse controls
b




 112 63/49 IlluminaHumanOmniExpr
essBeadChip 
MLPA & qPCR 
 RE 109   
 ARE 3   
Population controls
d
  2256 1179/1077  
 PopGen 1006  Affymetrix 6.0 





GGE 1408  Affymetrix 6.0 
Focal Epilepsy cohort
f






319  Various techniques
33
  
Deletion cases with epilepsy 37/202   
Duplication cases with epilepsy 22/117   
 
Table Legend 
Supplementary Table 1 Summary of the Samples Used in This Study 
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a) Patients were recruited by collaborating centers of the EuroEPINOMICS-COGIE 
initiative. Samples were collected at the Department of Neurology, Medical University 
of Vienna, Austria and at the Department of Neuropediatrics, University Medical 
Clinic Giessen, Germany. 98 Samples were collected via multiplex pedigrees the 
remaining 183 samples were all single patients. Rolandic Epilepsy (RE); Landau-
Kleffner syndrome (LKS), atypical benign partial epilepsy (ABPE) and electrical 
status epilepticus in slow wave sleep (CSWS) are subsumed under atypical Rolandic 
Epilepsy (ARE). b) In-house controls matched for analysis platform and geographic 
region. Population-based epidemiological controls drawn from the HNR (Heinz 
Nixdorf RECALL) study consisting of males and females aged 45 to 75 from the Ruhr 
area in Germany (n=1317) and additional in-house German control population 
(n=195). c) Additional RE/ARE patients recruited by collaborating centers of the 
EuroEPINOMICS-COGIE initiative and collected at the Department of Neurology, 
Medical University of Vienna, Austria (n=34). RE patients collected at the Epilepsy 
Research Centre, Melbourne Brain Centre, Department of Medicine, University of 
Melbourne, Australia (n=78) d) German control subjects available from the PopGen 
biobank (Population-Based Recruitment for Genetics Research) and KORA 
(Cooperative Health Research in the Region of Augsburg) e) genetic generalized 
epilepsy (GGE) patients collected by the EPICURE Project, for further description 
see (Lal et al., 2013) f) patients with mesial temporal lobe epilepsy (mTLE) provided 
by the Department of Neuropathology, University of Bonn Medical Center, Bonn, 
Germany g) 16p11.2 rearrangement carriers recruited for neurodevelopmental 
disorders (ND) including : developmental delay (DD), intellectual disability (ID) and 
severe learning disorders (LD) through a network of more than 30 European 
cytogenetic centers. 
 




Supplementary Table 2 CNV TaqMan Assay probes for the validation of the 16p11.2 
and 15q11.2 duplications. 
3.2.3.1 TaqMan CNV Assays 
3.2.3.2 Gene 3.2.3.3 AssayID 3.2.3.4 CNV 
3.2.3.5 QPRT 3.2.3.6 Hs02383672_cn 3.2.3.7 16p11.2 
3.2.3.8 SEZ6L2 3.2.3.9 Hs01431215_cn 3.2.3.10 16p11.2 
3.2.3.11 MAPK3 3.2.3.12 Hs02001681_cn 3.2.3.13 16p11.2 
3.2.3.14 CYFIP1 3.2.3.15 Hs02065338_cn 3.2.3.16 15q11.2 
 
Supplementary Table 3. Frequency of different type of epilepsies in the 16p11.2 
European consortium 
  Partial Generalized Infantile 
spasms 
Unspecified 
DUP N=117 (%) 9 (7.7) 3 (2.5) 3 (2.5) 7 (6) 
DEL N=202 (%) 12 (6) 7 (3.4) 2 (1) 16 (8) 
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Supplementary Table 4 Clinical features, MRI and EEG of individuals with RE/ARE from the 
16p11.2 European consortium 
PID: Patient Identity; RE: Rolandic Epilepsy; ARE: Atypical Rolandic Epilepsy; LKS: 
Landau-Kleffner Syndrome; W/H/HC: Weight, Height, Head Circumference; CTS: Centro-
Temporal Spikes; ESES: Electrical Status Epilepticus during Sleep ; VIQ: Verbal 
Intelligence Quotient; NVIQ: Non Verbal Intelligence Quotient; FSIQ: Full Scale Intelligence 
Quotient; NA: Not Available; a) Wechsler Intelligence Scale Children-Third Edition 
performed at 10 years old; b) Wechsler Preschool and Primary Scale of Intelligence-Third 
Edition performed at 5,6 years old.  
Reference 
Lal D, Trucks H, Moller RS, Hjalgrim H, Koeleman BP, de Kovel CG, et al. Rare exonic 
deletions of the RBFOX1 gene increase risk of idiopathic generalized epilepsy. Epilepsia 
2013; 54: 265-71. 
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3.2.4 DEPDC5 in RE (in revision) 
 
Lal D*, Reinthaler EM*, Schubert J*, Muhle M, et al., (2013) DEPDC5 mutations in Rolandic 
epilepsy spectrum. Annals of Neurology (submitted) 
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DEPDC5 mutations in Rolandic epilepsy spectrum 
Dennis Lal, MS,1,2,3,* Eva M. Reinthaler, MS,4,* Julian Schubert,5,6,* Hiltrud Muhle, MD,7 
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Two recent studies have identified DEPDC5 loss-of-function mutations in familial focal 
epilepsy with variable foci, autosomal dominant nocturnal frontal epilepsy and familial 
temporal lobe epilepsy. We report on four patients with classic Rolandic epilepsy and 
novel variants in DEPDC5, one with a truncating effect. In addition, we identified three 
families with atypical phenotypes carrying truncating mutations in DEPDC5. The 
detected variants were all novel, inherited and present in all family members exhibiting 
the epilepsy trait clinically or electroencephalographically. Altogether, our findings 
suggest that mutations of DEPDC5 contribute to the genetic variance of genetic focal 
childhood epilepsy syndromes including Rolandic epilepsy. 
 
Key words:  
DEPDC5, Rolandic epilepsy, focal genetic epilepsy, focal idiopathic epilepsy, mutation, 
gene 
 




Rolandic epilepsy (RE), or benign epilepsy with centrotemporal spikes (BECTS), is a 
common focal epilepsy syndrome of childhood.1,2 RE is considered related to much 
rarer, less benign epilepsy syndromes, referred to as atypical Rolandic epilepsy (ARE) 
by some authors.3 Notably, “atypical benign partial epilepsy” (ABPE) with astatic 
seizures and atypical absences,4,5,6 Landau-Kleffner syndrome (LKS) with acquired 
speech dyspraxia, epileptic encephalopathies with continuous spike-and-wave during 
sleep (CSWS), and “epilepsy aphasia spectrum” with language delay and autistic 
features7,8 may belong to a spectrum with RE on its benign and CSWS/LKS on its 
severe end.3,6,8 
Mutations in DEPDC5 encoding the Dishevelled, Egl-10 and Pleckstrin [DEP] domain-
containing protein 5, have recently been identified as the major cause of inherited focal 
epilepsies including familial focal epilepsy with variable foci (FFEVF), autosomal 
dominant nocturnal frontal epilepsy (ADNFLE) and familial temporal lobe epilepsy 
(FTLE).9,10 DEPDC5 is a member of the GATOR2 complex that interacts with the mTOR 
complex1 which is potentially accessible by mTOR inhibitors.11 
The present study tested whether DEPDC5 mutations contribute to genetic focal 
childhood epilepsies. 
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Patients and Methods  
DEPDC5 screening cohort 
To investigate an involvement of DEPDC5 in the etiology of focal epilepsies in 
childhood, two cohorts comprising 290 European patients were included in the DEPDC5 
mutation screen: 
Patients - RE cohort 
Patients of European ancestry were recruited at several centers from Germany, Austria 
and Canada. The study was approved by all respective local institutional review boards. 
The investigated cohort consisted of index patients selected from 88 multiplex families 
with at least two affected siblings. In 88, families at least one of the affected probands 
suffered from RE or ARE, the second affected sibling presented either with RE, ARE or 
the EEG trait only. Of all 88 familiar index patients tested (male=54, female=34), 73 
presented with RE, 12 with ARE, and 3 with ESES. In addition we included 120 non-
familial patients (69 males, 51 females). Of these sporadic patients 111 suffered from 
RE, and nine from ARE.   
Sequencing - RE cohort  
For all 208 patients, exome data were generated which featured an average coverage 
>30x for 77% of the target sequences (for details see12). Variants were filtered for high-
quality rare variants in DEPDC5 by comparison to an in-house variation database, 
dbSNP build 137 (www.ncbi.nlm.nih.gov/projects/SNP/), 1000Genomes database 
(www.1000genomes.org/), and the Exome Variant Server 
(http://evs.gs.washington.edu/EVS/). Variant validation and segregation analyses were 
performed by Sanger sequencing following standard protocols. 
Screening for DEPDC5 mutations in non-Rolandic genetic focal epilepsy syndromes 
Furthermore, mutations in DEPDC5 were screened in a cohort of 82 families comprising 
a broad spectrum of genetic focal epilepsy phenotypes, with variable degrees of 
intellectual disability. This cohort was analyzed using a targeted next generation 
sequencing (NGS) panel approach covering 285 epilepsy-associated genes as 
described previously.13 




Detection and inheritance testing of rare variants in DEPDC5 
Mutational screening of DEPDC5 in 208 RE patients identified a total of two novel, 
heterozygous truncating mutations (Fig 1; Fig 2, Table 1), including a frameshift variant 
p.I1139Mfs*24 (c.3417delA; according to reference transcript NM_001242896.1, 
reference protein NP_001229825.1) and a splice site variant c.59-1G>C . Furthermore, 
we detected two novel nonsense variants p.R865* (c.2593C>T) and p.R243* 
(c.727C>T). In addition, we identified three missense mutations (p.V272L, c.814G>T; 
p.V90I, c.268G>A; p.S1153G, c.3457A>G) of uncertain significance in the RE cohort 
(Figure 1). The p.V272L and the p.S1153G mutations are predicted to be disease 
causing whereas the p.V90I exchange is predicted to effect splicing by in silico analysis 
using the Mutation T@ster Tool (http://www.mutationtaster.org). The variants were 
distributed through the whole gene and protein (Fig 2). None of the seven DEPDC5 
variants was present in dbSNP137, the 1000 Genomes Project database or in the 6,503 
exomes for which variants are currently listed in the National Heart, Lung, and Blood 
Institute (NHLBI) exome variant server (EVS, accessed 06/2013) database. One stop 
codon generating variant and one frameshift variant in DEPDC5 have been annotated in 
the 6,503 exomes listed in the EVS database, whereas no deleterious mutation was 
observed in >450 exomes of our in-house database fulfilling the same exome 
sequencing quality filters (various non-epilepsy projects; about 80% Caucasian 
ancestry). DEPDC5 mutations occurred significantly more often in the RE cohort of 
affected individuals (2/208; P = 0.005 Fisher´s exact test). 
Familial Segregation analysis  
The segregation of DEPDC5 variants identified in the RE index patients were tracked in 
seven families (Fig 1). In Family 3 the mutation was introduced by the grandfather and 
transmitted to the index patient by the mother. In the remaining five families the variants 
were inherited, once maternally and four times paternally. Four out of 18 variant carriers 
were affected by RE, one by Rolandic epilepsy persisting to adulthood (REPA), two by 
ABPE and two by unclassified epilepsies as well as one affected by unclassified 
cryptogenic epilepsy. Therefore, the penetrance for the epilepsy is incomplete. All 
tested individuals exhibiting seizures carried mutations in DEPDC5. Notably, we cannot 
rule out that seizure-free family members might have expressed the RE-characteristic 
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CTS EEG-trait at younger age, considering its age-related expression with maximum 
manifestation during childhood.  
Clinical features of individuals with deleterious DEPDC5 mutations  
Family 1 (p.I1139Mfs*24; c.3417delA) 
The index patient (F1-II.1) was diagnosed (classic) RE. 
Family 2 (c.59-1G>C, splice site) 
The male index patient (F2-II.1; c.59-1G>C) suffered from sensorimotor seizures of his 
right arm and revealed a characteristically shaped fronto-central sharp wave focus. He 
was diagnosed with RE and treated successfully with carbamazepine. After weaning the 
medication seizures reoccurred. The epilepsy was tentatively labeled “RE persisting to 
adulthood” (REPA in fig.1). His younger sister (F2-II-2; c.59-1G>C) presented with 
atypical absences (starring attacks) at age 3.5 years. Centrotemporal spikes were 
recorded bilateral at age 3.5 years, and left sided only at age 5.5 years. At age 8 years 
she suffered from repeated exercise-induced atypical absences preceded by an 
unspecific aura. She is seizure-free under ongoing oxcarbazepine therapy. The epilepsy 
was classified as ABPE (RE with atypical absences). 
Family 3 (p.R865*; c.2593C>T) 
The mother (F3-II.1; p.R865*) presented atonic seizures, starting at age 3 years, without 
any intellectual deficits. First documented EEG at 9 years and later at 9.5 years 
revealed temporo-posterior sharp waves bilateral. Since age 10 years she remained 
seizure-free without medication. Repeated EEG recordings were normal. The benign 
epilepsy is consistent with ABPE (RE with astatic seizures). Her son (F3-I.1, p.R865*) 
expressed myoclonic, atonic, and generalized tonic-clonic seizures started already at 
age 12 weeks. The epilepsy proved therapy-resistant and the child´s development 
remained severely impaired. The epilepsy was labeled unclassified cryptogenic focal 
epilepsy. The grandfather in this family (F3-III.2) suffered from a unclassified epilepsy 
(no more details available). 
Family 4 (p.R243* ; c.727C>T) 
The father (F4-II.2, DNA not available for testing) of our index patient reportedly had a 
focal epilepsy that resolved spontaneously during adolescence, possibly consistent with 
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RE. The available index patient (F4-I.3, p.Arg243*) however, did not present with a 
benign course. The patient´s seizures started at age 8 month. At age 2 years he 
showed myoclonic seizures with centro-temporal spikes, later during adulthood focal 
tonic seizures and multifocal spikes were documented. The epilepsy syndrome 
remained unclassified.  
 
Clinical features of individuals with DEPDC5 missense mutations 
Family 5 (pV272L; c.814G>T), Family 6 (p.V90I; c.268G>A), Family 7 (p. S1153G; 
c.3457A>G) 
For all index patients in these families (F5-II.1, F6-II.1, F7-II.1) the epilepsy was 
diagnosed as (classic) RE. In Family 5 the mutation carrying healthy brother (F5-II.2; 
pV272L) also displayed a characteristic EEG focus at age 4.9 years.  




Our DEPDC5 screen revealed in total seven rare mutations, of those four are predicted 
to be severely damaging due to the insertion of a stop codon or splice site alterations, 
whereas the missense variations are of uncertain significance. However, in silico 
analysis predicted two out of three missense variants as disease causing and one 
modifying splicing. Five families were part of our initial RE screening cohort (Fam. 
1,2,5,6 and 7). Two families (Fam. 3 and 4) were members of the second cohort 
comprising 82 families with unclassified genetic focal epilepsies. 
The observed penetrance in the analyzed families is like in previous reports 
incomplete.9,10 One truncating mutation (Family 1) and three missense variants 
(Families 5-7) were found in individuals that were diagnosed as typical RE. The 
observed frequency of 2% (4/208) is lower compared to the previous reports on familial 
focal epilepsy with variable foci, autosomal dominant nocturnal frontal epilepsy and 
familial temporal lobe epilepsy.9,10 In Family 2 carrying the tentative diagnosis “Rolandic 
epilepsy persisting to adulthood” a splice site variant was detected. In today’s view this 
family might also receive the diagnosis of “familial focal epilepsy with variable foci”. 
However, EEG records in this family repeatedly reported EEG findings characteristic for 
RE. Two additional families (Fam. 3 and 4) revealed a more or less private phenotype 
that differs greatly between affected individuals including intractable epilepsy and 
cognitive impairment.  
In summary, our results strengthen DEPDC5 as a focal epilepsy gene and extend the 
DEPDC5-related phenotypic spectrum to RE and related childhood epilepsies. 




Table RE patients with DEPDC5 variants 
 
Clinical characteristics of DEPDC5 variation carriers. RE= Rolandic Epilepsy, CTS= 
Centrotemporal spikes; ABPE= atypical benign partial epilepsy of childhood; REPA= Rolandic 
epilepsy persisting to adulthood; ShW= Sharpe Wave; GTCS=generalized tonic clonic seizure 
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Figure 1 Segregation of DEPDC5 affecting variants  
Segregation analyses could be performed for which DNA samples of family members were 
available. The respective DEPDC5 mutations (NM_001242896.1, NP_001229825.1) co-
segregated with a variable phenotype of either seizures or pathologic EEG patterns in most 
family members. Only a few individuals carried the respective familial mutation but did not 
present any clinical features, indicating incomplete penetrance of the mutations. However, 
subclinical phenotypes (e.g. EEG patterns) have not been investigated in these individuals 
(indicated by question mark). Abbreviations: n.a = DNA was not available for testing; RE = 
rolandic epilepsy; CTS = centrotemporal spikes; ABPE= atypical benign partial epilepsy of 
childhood, REPA = Rolandic epilepsy persisting to adulthood. 
Figure 2 Overview of DEPDC5 variants  
Top: Genomic localization and structure of the identified DEPDC5 variants 
(NM_001242896.1, hg19). Black dashes highlight the variant position. Bottom: Schematics 
of the DEPDC5 protein (NP_001229825.1), alterations are indicated. 
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3.3 Publications derived from additional projects 
3.3.1 NDUFV1 in IBSN (published) 
Lal D, Becker K, Motameny S, Altmüller J, Thiele H, et al. (2013) Homozygous missense 
mutation of NDUFV1 as the cause of infantile bilateral striatal necrosis. Neurogenetics 14: 
85–87. doi:10.1007/s10048-013-0355-z. 

























4 Overall discussion of the studies presented 
4.1 Identified variants associated with IGE 
We have previously shown that recurrent microdeletions at 15q11.2, 16p13.11 and 
especially 15q13.3 are genetic risk factors in up to 3% of common IGE syndromes 
and other neurodevelopmental disorders (Helbig et al., 2009; De Kovel et al., 2010; 
Mefford et al., 2010; Mulley et al., 2011). Our previous SNP-array CNV studies were 
limited to analysis of large recurrent microdeletions (>500 kb). Advances in CNV 
calling algorithms allowed us here to perform a deletion screening at single gene 
resolution. With regard to the low statistical power and CNV size variability, we 
focused on candidate microdeletions affecting genes involved in neuronal excitability.  
We were able to detect microdeletions in two genes, the first encoding the neuronal 
splicing regulator RBFOX1 (Lal et al., 2013a) and the second encoding the 
postsynaptic scaffolding protein gephyrin (GPHN; Dejanovic et al., in review). We 
demonstrated for the first time a significant association with deletions affecting 
RBFOX1 with a disease (Lal et al., 2013a), thereby supporting previous single case 
reports relating RBFOX1 deletions with a broad range of neurodevelopmental 
disorders including epilepsy (Bhalla et al., 2004; Martin et al., 2007; Gallant et al. 
2011). All RBFOX1 deletions identified were located within the highly conserved 5’-
untranslated exons and are predominantly expressed in brain, suggesting that the 5'-
terminal RBFOX1 region contains important regulatory elements (Damianov et al., 
2010), which when lost might alter translation efficiency and mRNA stability (Wang et 
al., 2005). Consistent with our findings, the structural genomic variations of the 
RBFOX1 gene reported previously in three single patients with neurodevelopmental 
disorders, including epilepsy, also disrupted the 5'-terminal RBFOX1 exons (Bhalla et 
al., 2004; Martin et al., 2007; Gallant et al. 2011). Furthermore, a recent study 
published after our IGE study, could identify additional 12 deletions in RBFOX1 all 
affecting the 5'-terminal RBFOX1 exons in a cohort of 2124 pediatric patients with 
neurodevelopmental diseases (Zhao 2013). Six out of the 12 deletion carriers had 
epilepsy.  
In our study on GPHN, we identified two patients with deletions and none in 2792 
controls (Dejanovic et al., in revision). These findings are in line with a recent study 




neurodevelopmental disorders (P = 0.009; 6/8775 cases versus 3/27019 controls) 
and found that three out of five GPHN microdeletions tested for inheritance arose as 
de novo events (Lionel et al., 2013). In our study, we furthermore present additional 
functional data elucidating the molecular mechanisms by which the N-terminal GPHN 
deletions cause dysfunctional GABAergic synaptic inhibition and thereby increase 
susceptibility of IGE (Dejanovic et al., in revision). Both GPHN deletions affected 
exons of the gephyrin G-domain, alike previously reported GPHN deletions (Lionel et 
al., 2013). We were able to show that one of our truncated gephyrin transcripts is 
stably expressed in human cells and perturbs the clustering of wild-type gephyrin at 
inhibitory synapses in cultured mouse hippocampal neurons in a dominant-negative 
manner. This effect is consistent with previous observations where stress-induced 
irregular splicing of GPHN resulted in curtailed postsynaptic gephyrin and GABAA α2 
receptor scaffolds (Förstera et al., 2010). In contrast, the other GPHN deletion 
causes a frameshift resulting in a premature stop codon (p.V22Gfs*7; 
NP_001019389.1) and hence translating into a short non-functional protein, which 
most likely leads to haplo-insufficiency of the gene. Our in vitro analysis showed a 
reduced amount of the synaptic γ-aminobutyric acid type A receptor (GABAAR) in the 
presence of the truncated Δ5-9 gephyrin (Dejanovic et al., in review). This pathogenic 
alteration results in a functionally convergent effect with a reduced GABAergic 
synaptic inhibition similar to that observed with mutations of genes encoding 
GABAAR subunits (GABRA1, GABRB3, GABRG2 and GABRD) in rare families with 
dominantly inherited IGE syndromes (for reviews see Macdonald et al., 2013; 
Cossette et al., 2012). 
In summary, we detected a significant statistical association of RBFOX1 deletions 
with common idiopathic epilepsies (Lal et al., 2013a; Lal et al., 2013b). In addition, 
we provided genetic, functional and neurophysiological evidence that structural 
exonic microdeletions affecting the gephyrin G-domain can increase neuronal 
excitability by an impairment of GABAergic synaptic inhibition, and thereby confer 
susceptibility to IGE (Dejanovic et al., in revision). Taken together with our previous 
findings (Helbig et al., 2009; De Kovel et al., 2010), our results demonstrate that also 
partial genomic deletions of genes collectively account for a significant fraction of the 
heritability of common IGE syndromes. This observation is in line with studies on 




known risk CNVs are rare and confer substantial effects on risk (odds ratios 3–30; 
Kirov et al., 2013). 
4.2 Identified variants associated with RE-spectrum epilepsies 
Despite the strong genetic contribution to the CTS-EEG trait, as shown in several 
family studies, the etiology of RE/ARE is largely unknown (Neubauer et al., 1998; Bali 
et al., 2007; Strug et al., 2009). In the past, a significant genetic etiology of RE was 
questioned because of low concordance rates in monozygous twins (Vadlamudi et 
al., 2004, 2006). In contrast, a recent study suggests that RE has a genetic 
component consistent with complex inheritance based on the increased frequency of 
epilepsies in relatives of RE patients (Vears et al., 2012). To clarify this question we 
performed a comprehensive genomic screen for exonic coding mutations in 242 
RE/ARE patients as well as CNVs in 308 RE/ARE patients representing the largest 
cohort of RE-spectrum patients investigated up to date. 
We demonstrate that mutations and CNVs in the GRIN2A gene encoding the NMDA-
receptor NR2A subunit represent a major genetic risk factor in 7.5% of children with 
idiopathic focal epilepsies including RE (Lemke et al., 2013). This is of particular 
interest as NMDA receptors are promising treatment targets. It has been shown that 
NMDAR antagonists have antiepileptic effects in both clinical and preclinical studies 
(Ghasemi et al., 2011). At least 20 NMDAR antagonists are marketed or in 
development for a broad range of neurology indications. (Osherovich et al., 2013). 
There is some evidence that conventional antiepileptic drugs may also affect NMDAR 
function (Ghasemi et al., 2011). Based on our (Lemke et al., 2013) and convergent 
results of other groups (Lesca et al., 2013; Carvill et al., 2013) commercial 
companies (e.g. Naurex, Inc.) started physiological characterization of epilepsy-
associated mutations in cell culture and animal models (Osherovich et al., 2013; 
http://www.naurex.com/).  
We also found that exonic deletions and truncating mutations of RBFOX1 as well as 
RBFOX3 contribute to the genetic variance of common idiopathic epilepsy 
syndromes (Lal et al., 2013a; Lal et al., 2013b). In addition, our present results 
demonstrate that mutations in DEPDC5 predispose specifically to focal epilepsies 
including RE (Dibbens et al., 2013; Ishida et al., 2013; Lal et al., in revision). 




important genetic risk factor for the RE-spectrum epilepsies (Reinthaler et al., in 
revision), thereby further supporting the associations between 16p11.2 duplications 
and early-onset neurodevelopmental disorders (Bijlsma et al., 2009; Jacquemont et 
al., 2011; McCarthy et al., 2009; Shinawi et al., 2010; Walters et al., 2010; Weiss et 
al., 2008; Zufferey et al., 2012). In summary, we were able to identify genetic risk 
factors in a significant fraction (~10%) of RE and ARE patients investigated in our 
study cohort. These results prove a significant genetic contribution to RE/ARE that 
was challenged previously (Vadlamudi et al., 2004, 2006). 
4.3 Epilepsy genetics 
Epilepsy is one of the most common neurological disorders, characterized by 
recurrent unprovoked seizures due to neuronal hyperexcitability and abnormal 
synchronization (Hauser et al., 1993). We have genetically investigated two common 
major subtypes of idiopathic epilepsies (i) idiopathic generalized epilepsies (IGEs) 
and (ii) the RE-spectrum epilepsies. Both groups are distinguishable by their leading 
seizure types, age-dependent onset and electroencephalographic criteria. For IGE a 
whole string of literature supports a strong genetic etiology (reviewed by Helbig et al., 
2008) whereas for RE the genetic impact in disease has been challenged previously 
(Vadlamudi et al., 2004, 2006). Both idiopathic epilepsies were expected to have a 
complex genetic architecture (Figure 3).  
 
Figure 3 Expected genetic factors for idiopathic epilepsies. Dashed lines indicate the expected genetic contribution 




We have identified genetic risk factors in RBFOX1and RBFOX3 (Lal et al., 2013a; Lal 
et al., 2013b), GRIN2A (Lemke et a., 2013), GPHN (Dejanovic et al., in revision), 
DEPDC5 (Lal et al., in revision) as well as at the locus 16p11.2 (Reinthaler et al., in 
revision). However, these variants are not prevalent in a similar frequency in all 
epilepsy types. As an example, we detected GRIN2A mutations (Lemke et al., 2013) 
in a broad range of focal childhood epilepsies but we did not observe these in 
epilepsies with age-of-onset in adulthood (data not shown). Furthermore, DEPDC5 
mutations are likely to be responsible for a fraction of focal epilepsies regardless of 
age of onset (Dibbens et al., 2013; Ishida et al., 2013; Lal et al., in revision) but not 
for generalized epilepsies (data not shown). The 16p11.2 duplication is absent in 
temporal lobe epilepsies as well as IGE syndromes but constitutes, besides the RE-
spectrum (Reinthaler et al., 2013), an important genetic risk factor for autism (Weiss 
et al., 2008) and obesity (Jacquemont et al., 2011). Otherwise, exonic deletions of 
RBFOX1 are present in both types of common idiopathic epilepsies. Our identified 
CNVs and gene mutations are not specific to epilepsy. Notably, the variants are also 
implicated in other epilepsy types and a broad range of neurodevelopmental 
diseases including autism, schizophrenia and intellectual disability (Coe et al., 2012; 
Helbig et al., 2009; De Kovel et al., 2013; Mefford et al., 2010; Mulley et al., 2011; 
Reutlinger et al., 2010; Lesca et al., 2012; Lionel et al., 2013; Förstera et al., 2010; 
Bhalla et al., 2004; Martin et al., 2007; Gallant et al., 2011, Dibbens et al., 2013; 
Ishida et al., 2013).  
The penetrance for all identified variants is incomplete as illustrated by the presence 
of apparently clinically unaffected variant carriers in the families. This is in agreement 
with observations from large recurrent microdeletions previously identified in IGE 
(Helbig et al., 2009; Dibbens et al., 2009; De Kovel et al., 2010) and a range of 
neurodevelopmental disorders (reviewed by Carvill et al., 2013). Most likely, many 
identified variants impair basic neurodevelopmental processes that affect a variety of 
physiologic functions. However, a close relation between severe childhood epilepsies 
and autism has been expected (reviewed in Coe et al., 2012). Likewise, the severity 
and expressivity of the phenotypes varied considerably in all our studies between 
affected members of the same family. Thus, the individual epilepsy phenotype is 
probably further specified by the interplay of environmental influences with genetic 
background following an oligo-/polygenic inheritance model with substantial genetic 




Based on our small cohort sizes and the large amount of rare variants per individual 
we had insufficient statistical power to analyze our data at a genome-wide level. 
Extrapolation of effect sizes and frequencies from published studies show that 
thousands of individuals are required to reach acceptable statistical power in WES 
studies (Kiezun et al., 2012). Therefore, the presented studies are based on a priori 
assumptions of a candidate gene/locus hypothesis. Consequently, a potentially large 
part of the individual genetic disease predisposition is not explored. In the future, the 
constantly increasing study sizes through worldwide collaborations may allow well-
powered screens for detection of mutations with major to modest effect sizes.  
Furthermore, the individual epilepsy-causing genetic predisposition is also likely to be 
influenced by common variants (Mullen et al., 2009). Studies on common genetic 
variants like our recently published genome-wide association study for IGE (3020 
IGE patients and 3954 controls) have identified common susceptibility loci with minor 
effects (EPICURE Consortium et al., 2012). The translation of these results into 
biological context is challenging (EPICURE et al., 2012, reviewed by Edwards et al., 
2013). In general, our ongoing WES-based mutation screening studies solely focus 
on the CCDS-defined protein-coding regions. However, recent publications by the 
ENCODE project have assign biochemical functions to 80% of the genome, 
especially in genomic regions outside of the well-studied protein-coding regions 
(ENCODE Project Consortium et al., 2012), opening new avenues for disease 
research. Thus, studies on candidate genes, novel epilepsy associated genes, non-
protein coding regions of the genome and the epigentic landscape are warranted to 
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6 Summary / Zusammenfassung 
6.1 Summary 
Epilepsy is one of the most common neurological disorders characterized by 
recurrent unprovoked seizures due to increased neuronal hyperexcitability and 
abnormal synchronization. I have explored the genetic architecture of the most 
common types of idiopathic epilepsies, the idiopathic generalized epilepsies (IGEs) 
and the spectrum of idiopathic focal epilepsies related to rolandic epilepsies (REs). 
Both groups are distinguishable by the leading seizure types, age-dependent onset 
and electroencephalographic criteria. For IGEs a complex genetic contribution is 
indicated from family and twin studies, whereas the genetic basis of REs has been a 
matter of debate. At present, the majority of genetic factors predisposing to common 
idiopathic epilepsies remain elusive. The aim of the present studies was the 
molecular genetic dissection of genetic risk factors with strong epileptogenic effects 
in idiopathic epilepsies and the elucidation of their molecular pathways in 
epileptogenesis. Therefore, our group conducted copy number variation (CNV) 
analyses using high-resolution SNP arrays in two case-control cohorts comprising: i) 
1582 IGE and 2795 populations controls, and ii) 308 patients with RE-spectrum 
epilepsies and 1512 controls of European descent. In addition, we performed 
candidate gene sequence analysis in 242 patients with RE-spectrum epilepsies. With 
regard to the low power of our study samples for genome-wide scans, our current 
strategies focused on a candidate gene/locus approach of genes and CNVs that 
have been implicated in the pathogenesis of epilepsies and related 
neurodevelopmental disorders, as well as candidate genes with a presumed impact 
on neuronal excitability. In the present cumulative thesis, I report the results of our 
current CNV and sequence analyses of highly plausible candidate genes based on 
three peer-reviewed publications and another three manuscripts that are currently in 
revision.  
We are the first to show a significant statistical association for deletions affecting the 
neuronal splicing regulator RBFOX1 with idiopathic epilepsies (Lal et al., 2013a). 
Moreover, we also detected deletions and truncating mutations in RBFOX1 as well as 
in the neuronal splicing regulator RBFOX3 in the RE cohort (Lal et al., 2013b). We 
provide genetic, functional, and neurophysiological evidence that structural exonic 
microdeletions affecting the GPHN gene, which codes for the synaptic scaffolding 
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protein gephyrin, may increase neuronal excitability by an impairment of GABAergic 
synaptic inhibition and thereby confer susceptibility for IGE (Dejanovic et al., in 
revision). We also found that missense and truncating exonic mutations and 
microdeletions of the GRIN2A gene encoding the NMDA-receptor NR2A subunit are 
a major genetic risk factor in 7.5% of children with idiopathic focal epilepsies 
including RE-spectrum epilepsies (Lemke et al., 2013). Notably, mutations in the 
DEPDC5 gene, encoding DEP domain-containing protein 5, preferentially predispose 
to focal idiopathic epilepsies (Lal et al., in revision). Finally, screening for recurrent 
CNVs revealed 16p11.2 duplications as an important genetic risk factor for the 
spectrum of REs (Reinthaler et al., in revision), thereby further supporting the 
associations between 16p11.2 duplications and early onset neurodevelopmental 
disorders.  
In conclusion, our studies identified several genetic risk factors in a significant 
fraction of idiopathic epilepsy patients. Moreover, the present study is the first that 
clearly proves a genetic impact on the etiology of the common REs at the molecular 
genetic level. We are aware that our small samples sizes provide insufficient power 
for exome-wide rare-mutation or genome-wide rare-CNV association testing. Future 
large-scale studies are warranted to identify additional pathogenic variants to better 
understand the complex genetic architecture of the most common types of idiopathic 
epilepsies. 
  




Epilepsie ist eine der häufigsten neurologischen Erkrankungen, charakterisiert durch 
wiederkehrende, nicht provozierte epileptische Anfälle aufgrund neuronaler 
Übererregbarkeit sowie gesteigerter kortikaler Synchronisation. In der vorliegenden 
Arbeit wurde die genetische Architektur der beiden häufigsten Formen von 
idiopathischen Epilepsien, den idiopathisch generalisierten Epilepsien (IGE) und der 
idiopathisch fokalen Epilepsie (sog. Rolando Epilepsie, RE) untersucht. Beide 
Gruppen unterscheiden sich hinsichtlich ihrer charakteristischen Anfallstypen, dem 
altersabhängigen Auftreten und dem elektroenzephalographischen Muster. Familien- 
und Zwillingsstudien belegen eine vorwiegend genetische Disposition der häufigen 
IGE Syndrome, während die Beteiligung von genetischen Einflüssen an der Ätiologie 
der RE bislang umstritten war. Bei den häufigen idiopathischen Epilepsien ist die 
Mehrzahl der beteiligten genetischen Faktoren noch unbekannt. Das Ziel der 
vorliegenden Arbeit war die molekulargenetische Identifikation von genetischen 
Risikofaktoren. Aufgrund der geringen Größe unserer Kollektive war nur die 
Identifikation von Varianten mit starken epileptogenen Effekten möglich. Hierzu 
haben wir copy number variation (CNV)-Analysen mit hochauflösenden SNP-Arrays 
in zwei Patienten-Kontroll-Kohorten durchgeführt. Die Kollektive bestanden aus: i) 
1582 IGE-Patienten und 2795 Kontrollen mit europäischer Herkunft und ii) 308 
Epilepsie-Patienten aus dem RE-Spektrum und 1512 Populationskontrollen 
europäischer Herkunft. Darüberhinaus haben wir Kandidatengen Sequenzanalysen 
bei 242 Patienten mit RE durchgeführt. Im Hinblick auf die geringe statistische Größe 
unserer Studienkohorten waren unsere Strategien auf Kandidatengen/-lokus-Ansätze 
ausgelegt. Dafür wurden Kandidatengene und -CNVs ausgewählt, die eine Funktion 
in der synaptischen Transmission aufweisen oder bei anderen neurologischen 
Erkrankungen bereits als Risikofaktoren identifiziert wurden. In der vorliegenden 
kumulativen Dissertation berichte ich über die Ergebnisse unserer aktuellen CNV und 
Sequenzanalysen und beziehe mich auf drei veröffentlichte Manuskripte, sowie auf 
drei weitere Artikel, die sich derzeit in Revision befinden. 
 
Unsere Arbeiten belegen erstmals eine signifikante statistische Assoziation von 
Mikrodeletionen, die den neuronalen Spleiß-Regulator RBFOX1 betreffen, mit 
idiopathischen Epilepsien (Lal et al., 2013a). Ferner konnten wir nachweisen, dass 
Deletionen und loss-of-function-Mutationen von RBFOX1 und RBFOX3 in der RE-
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Kohorte auftreten (Lal et al., 2013b). Wir fanden genetische, funktionale und 
neurophysiologischen Belege dafür, dass exonische Mikrodeletionen in GPHN die 
neuronale Erregbarkeit durch eine Beeinträchtigung der GABAergen synaptischen 
Hemmung steigern und dadurch das Risiko für IGE erhöhen (Dejanovic et al., in 
Revision). Wir konnten ebenso belegen, dass missense- und loss-of-function-
Mutationen sowie Mikrodeletionen von GRIN2A, das für eine Untereinheit des 
NMDA-Rezeptors NR2A kodiert, einen genetischen Risikofaktor bei 7,5 % der Kinder 
mit idiopathischen fokalen Epilepsien darstellen (Lemke et al., 2013). Schließlich 
konnten wir zeigen, dass Mutationen in DEPDC5 präferentiell zu fokalen 
idiopathischen Epilepsien prädisponieren (Lal et al., in Revision). Unser Screening für 
rekurrente CNVs identifizierte 16p11.2-Duplikationen als signifikanten genetischen 
Risikofaktor für das Spektrum der RE-assoziierten Epilepsien (Reinthaler et al., in 
Revision). Dadurch konnten wir die Assoziation zwischen 16p11.2-Duplikationen und 
früh einsetzenden neurologischen Entwicklungsstörungen erhärten und das 
phänotypische Spektrum um die RE erweitern. 
 
Zusammenfassend haben unsere Studien mehrere genetische Risikofaktoren bei 
einem bedeutenden Anteil der idiopathischen Epilepsie-Patienten identifiziert. Die 
Ergebnisse unserer Untersuchungen belegen nunmehr das Vorliegen einer 
genetischen Disposition für die RE eindeutig. Große, multizentrische 
Studienkollektive werden die Vorrausetzung schaffen, um systematisch seltene 
Mutationen und CNVs zu identifizieren. Die Identifikation von weiteren genetischen 
Risikofaktoren wird die Grundlage zu einem besseren Verständnis der komplexen 
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